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ANT Altered Nuclear Transfer 
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HeLa HeLa cells were the first human cells to be 
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Glossary of terms 
 
Adenoviral Vector Any of a large group of viruses causing disease of the 
upper respiratory tract and conjunctiva, and also 
present in latent infections in normal persons; used to 
used to insert sequences into an organism's cells. 
Adult Stem Cells Adult stem cells are undifferentiated cells found 
throughout the body that divide to replenish 
dying cells and regenerate damaged tissues. 
 Antigen   A toxin or other foreign substance which induces an 
     immune response in the body, especially the  
     production of antibodies. 
 
Autonomy   The right or condition of self-government. 
 
Blastocyst Over the course of day five of development, the 
Morula begins to hollow out and fill with fluid. These 
additional characteristics transform it into what is 
known as the Blastocyst. 
Canavan Disease A progressive, fatal neurological disorder that begins 
in infancy. It is caused by an inherited genetic 
abnormality: the lack of an  essential enzyme causes 
deterioration of the white matter (myelin) in the brain, 
thereby preventing the proper transmission of nerve 
signals. 
 
Cell Differentiation  A biological process through which every cell, 
whether the liver, heart, or brain, takes on its role by 
specialising into a particular cell type, with a 
characteristic shape and function. 
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Cell de-differentiation The regression of a cell from a more specialized state 
back to a simpler state that confers pluripotency, 
giving rise to cells reminiscent of stem cells. 
Chromosomes A thread-like structure of nucleic acids and protein 
found in the nucleus of most living cells, carrying 
genetic information in the form of genes. 
 
Cognitive Of or relating to the mental processes, e.g. memory, 
judgement etc.  
Conception The moment when a sperm cell breaches the ovum, 
or egg.  
Consequentialism An ethical theory that human actions derive their 
moral worth solely from their outcomes or 
consequences. 
Culture Dish A shallow circular dish with a loose-fitting cover, used 
to culture bacteria or other microorganisms.  
Cryopreservation Is a process where cells, whole tissues, or any other 
substances susceptible to damage caused by 
chemical reactivity or time are preserved by cooling 
to sub-zero temperatures. 
Cytoplasm The material or protoplasm within a living cell, 
excluding the nucleus. 
Deontology An ethical theory that the morality of an action should 
be based on whether that action itself is right or wrong 
under a series of rules, rather than based on the 
consequences of the action. 
 
 
8 
 
Embryogenesis  Period of time which spans from the end of fertilisation 
(zygote stage) until the end of the eighth week of 
development, after which the developing human is 
referred to as a foetus. 
Embryonic Stem Cells  Stem cells which originate from an embryo. These 
cells are formed and extracted within the first four to 
five days after fertilization has occurred. 
Empirical Relying on or derived from observation or experiment. 
Ensoulment The point at which the soul is believed to enter the 
human body. 
Enucleated Cell A cell which no longer contains its nucleus. 
Epigenetic  Relating to or arising from non-genetic influences on 
gene expression. 
Epithelial The thin, membranous tissue that lines most of the 
internal and external surfaces of an animal's body. 
Fard Kifaya   Islamic term used to describe a collective religious 
    obligation. 
Fertilization  The process whereby two sex cells (an ovum and a 
sperm) fuse together to become a zygote. 
Fibroblast A cell in connective tissue which produces collagen 
and other fibres. 
Foetal Stem Cells These kinds of stem cells are derived from the tissue 
of aborted foetuses within the time frame of five to 
nine weeks post-fertilization. 
Foetus Animatus A Christian term used to refer to an embryo which had 
acquired a soul; literally translated as an animated 
embryo. 
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Foetus Inanimatus A Christian term used to denote an embryo before it 
acquired a soul; literally translated as an inanimate 
embryo. 
Gastrula Two weeks after fertilization, the cells of the inner cell 
mass of the blastocyst begin to form into distinct cell 
types which will form the embryo; it is now referred to 
as a Gastrula. 
Hadith An Islamic book of the sayings and actions of the 
Prophet Muhammad.  
Ijtihad Islamic term used to describe independent 
judgement. 
Implantation The point when the fertilized blastocyst attaches to 
the lining of the uterus/womb. 
Induced Pluripotent Stem Cells which have been created through the  
Stem cells application of transcription factors to a somatic cell. 
 
In utero Cultivated or developed within a womb. 
In vitro Cultivated or developed within a laboratory; usually 
within a culture dish and/or test tube. 
Inner Cell Mass (ICM) Consists of the mass of cells inside the early embryo 
that will eventually give rise to the definitive structures 
of the foetus.  
Lentoviral Vector An artificial construct which can deliver a significant 
amount of viral RNA into the DNA of the host cell and 
have the unique ability among retroviruses of being 
able to infect non-dividing cells. 
Mitochondria An organelle found in large numbers in most cells, in 
which the biochemical processes of respiration and 
energy production occur.  
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Mitosis A type of cell division that results in two daughter cells 
each having the same number and kind of 
chromosomes as the parent nucleus, typical of 
ordinary tissue growth. 
Moral Status A characteristic that we human moral agents attribute 
to entities, by virtue of which they matter morally for 
their own sake, so that we must pay attention to their 
interests or integrity when we consider actions that 
might affect them, regardless of whether other 
beings are concerned about them. 
 
Morula By dividing four or five times since fertilization, the 
formation of a solid ball of 16-32 cells called the 
Morula is formed. 
Multipotent Stem Cells Multipotent stem cells refer to the group of stem cells 
which can give rise to a limited number of specialised 
cells within the body but only those of a closely related 
family of cells. 
Oocyte An immature female sex cell, which after two cell 
divisions becomes an ovum. Contains 23 
chromosomes. 
Patent A government authority or license conferring a right or 
title for a set period, especially the sole right to 
exclude others from making, using, or selling an 
invention. 
Personhood The quality or condition of being an individual person. 
Pluripotent Stem Cells This category of stem cells can indefinitely produce 
specialised cells for any part of the body.  
Pre-embryo This term was employed in order to differentiate 
between an early embryo of up to 14 days of age 
since fertilisation, and one of later development.  
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 Primitive Streak  The faint streak which is the earliest trace of the  
      embryo in the fertilized ovum of a higher vertebrate. 
Qur’an   The Islamic book of faith. 
Retroviral Vector An artificial DNA construct derived from a retrovirus, 
used to insert sequences into an organism's 
chromosomes. 
Somatic Cell Any cell of a living organism other than the 
reproductive cells. 
Sperm Male sex cell. Contains 23 chromosomes.  
Stem Cell Line  Refers to stem cells which have been isolated from 
an organism and transferred to an in vitro culture 
within a laboratory, whereby the stem cells multiply 
indefinitely. 
Supernumerary Present in excess of the normal or requisite number. 
Surrogate A substitute; especially a person deputizing for 
another in a specific role or office. 
Totipotent Stem Cells These are stem cells which possess the ability to 
differentiate into all the different kinds of cells within 
the human body, and so are able to give rise to an 
entire organism.  
Transcription Factor Proteins involved in the process of converting, or 
transcribing, DNA into RNA. These factors initiate and 
regulate the transcription of genes. 
Transgene A transgene is a gene or genetic material that has 
been transferred naturally, or by any of a number of 
genetic engineering techniques from one organism to 
another. 
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Utilitarian A branch of Consequentialism; the doctrine that 
actions are right if they are useful or for the benefit of 
a majority. 
Viral Vector Viral vectors are tools commonly used by 
molecular biologists to deliver genetic 
material into cells. 
Zygote The product of fertilization – one cell containing all 46 
chromosomes. 
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Abstract 
The field of stem cell technology has seen an exponential growth over the last 
decade. Due to this, little attention has been paid as to whether this new 
technology adequately improves on previous research models, or indeed if it 
causes any ethical or legal issues itself. Of particular interest is whether Induced 
Pluripotent Stem Cells resolve the ethical and legal issues which have been 
generated by Human Embryonic Stem Cells. The ethical issues of note relate to 
the definition of personhood and moral status, the debate on when these can be 
ascribed, the consequences of utilising embryos for research, and whether the 
new method of inducing pluripotency stimulates any ethical issues itself. The 
central legal issues revolve around the diverse regulations which guide current 
research around the world, legal definitions regarding a child’s right to life, 
whether such a right exists, the scope of consent, the limits of confidentiality, as 
well as whether current patent guidelines adequately stimulate research into this 
important area of medical development.  The expected outcome of this 
exploration is that where induced pluripotency may appear to alleviate most of 
the ethical issues raised by human embryonic stem cells, the same may not be 
affirmed to a similar extent in the legal sphere, rather it is suggested that the 
employment of this new alternative method of creating stem cells may complicate 
the legal matters further. It is recommended that further investigation to 
harmonizing legal definitions as well as updating current regulations occurs, in 
order to avoid the exploitation of potentially vulnerable groups of the population.  
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1. Introduction 
 
“Stem cell research can revolutionise medicine, more than anything since 
antibiotics.”  
       -Ron Reagan(1) 
What if someone told you that you could potentially live forever? That you'd never 
die from a degenerative disease or otherwise? What if the science exists and all 
we're waiting for is a breakthrough? 
Human stem cell research has made astonishing progress since the discovery of 
embryonic stem cells in 1998. While stem cell research has given hope to those 
who suffer from degenerative and neurological disorders such as Alzheimer’s or 
Parkinson’s Disease, ethical and legal issues related to human embryonic stem 
cells have tainted the popular appeal of this important medical research, in some 
countries causing severe research restrictions or a complete ban on pursuing 
such medical exploration.   
This ethical and legal backlash is focused on the consequences to an embryo 
when it is used as a means to obtain human embryonic stem cells, namely its 
destruction. An overview of the method and consequences of accessing and 
collecting human embryonic stem cells will lay the foundation for the remainder 
of the thesis. Understanding the moral aversion to human embryonic stem cell 
research as well as the ethical and social issues which this research stimulates, 
will help the reader fully understand and appreciate the necessity of establishing 
an alternative method of obtaining human stem cells. The most recent method, 
which has been hailed as the moral and ethical alternative, which is focused on 
in this examination is that of inducing pluripotency within human adult somatic 
cells i.e. induced pluripotent stem cells.  
The aim of this thesis is to establish if this new alternative method of inducing 
pluripotency within adult somatic cells adequately addresses or resolves the 
ethical and legal issues created by the research and use of human embryonic 
stem cells.  
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This analysis will firstly explore the background of stem cell research in its 
entirety; focusing on what stem cells are, the difference between certain kinds of 
stem cells, where these cells can be found, and their potential applications in 
medicine. The discourse will then go into more detail concerning human 
embryonic stem cells and the specific information concerning the methods 
through which these may be obtained. After this, the methods and implications of 
induced pluripotent stem cells will be explored, focusing on the development of 
this new approach, the different methods which can create these cells, and if any 
problems currently exist with this alternative method. 
To conclude whether or not induced Pluripotent Stem Cell research alleviates the 
ethical and legal issues stimulated by human embryonic stem cell research, a 
detailed exploration of the issues is essential.  
The ethical issues of human embryonic stem cells explored in this thesis 
comprise of the diverse understandings of the beginning of life and its connection 
to personhood, the differing religious perspectives which impact this 
understanding, the interpretation and application of language employed within the 
start of life debate, the potential of an unborn embryo, the social issues of utilising 
alternative sources of human embryonic stem cells which have been noted as 
possibly commercialising the human body as well as prompting the unethical 
creation of intentionally maimed embryos.  
These ethical issues will then receive comparative analysis with the alternative 
method of inducing pluripotency in adult somatic cells. Specifically, each ethical 
issue will be addressed in the context of induced pluripotent stem cells as a viable 
alternative to human embryonic stem cells. It is suggested that through this 
analysis it may become apparent that induced pluripotent stem cells obviate or 
resolve many of the ethical issues generated through human embryonic stem cell 
research. As well as this, the method of inducing pluripotency may stimulate its 
own ethical concerns, such as unwanted outcomes and issues of justice, which 
will also receive further elucidation.  
Consequently, the present legal context governing stem cell research, collection 
and storage will be examined as well as the implications these regulations have 
on the progress of this significant area of medical research within certain leading 
countries in the field, for example the UK and the US.  
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Within this context, the problems created by legal definitions and the right to life 
will be examined, as well as the important legal parameters of consent and 
confidentiality, and lastly, the area of patenting stem cells.  
These issues will be comparatively critiqued against the background of induced 
pluripotent stem cells as a viable alternative to human embryonic stem cells. It is 
believed that where induced pluripotency may appear to alleviate most of the 
ethical issues raised by human embryonic stem cells, the same may not be 
affirmed to a similar extent in the legal sphere. It is suggested that the 
employment of this new alternative method of creating stem cells may complicate 
the legal matters further; from the outset it appears uncertain as to whether the 
method of inducing pluripotency adequately resolves the legal issues caused by 
human embryonic stem cell research.  
However, the hopes and potential benefits of this medical technology are seen 
as being too great to ignore. If there is a possibility that an alternative, more 
ethically and legally moral, method of creating stem cells exists, is it not a duty 
for medical researchers to abandon traditional methods and employ the newer 
alternative? Before this can be answered, the primary question of this thesis 
needs to be thoroughly explored:  
Do Induced Pluripotent Stem Cells resolve the ethical and legal issues generated 
by Human Embryonic Stem Cells? 
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2. What are Stems Cells? 
 
There is little public understanding of the origin and potential of stem cells (2). 
This chapter will be outlining the discovery, research, classification, biological and 
scientific origins, applications, and possibilities of stem cells and stem cell 
research. Only once this basic foundation has been laid will a robust debate 
concerning the ethical, legal and even scientific issues of stem cells be possible.  
The initial proposition that stem cells existed remained "largely hypothetical until 
research on survivors of the 1945 nuclear bombings was carried out and the term 
re-emerged to describe cellular regeneration mechanisms found to exist 
throughout the body" (3). This discovery was made through the assessment that 
even though red blood cells typically have a life span of four months, the human 
body continued to generate fresh blood cells to replace the ones lost. "This 
regeneration is guaranteed by stem cells residing in bone marrow, which can 
differentiate into any one of the various types of blood cells" (3). Such cellular 
regeneration mechanisms were further explored and it was found that a particular 
type of special cell - a stem cell - was capable of regenerating not only red blood 
cells, but other types of specialised cells. The main focus then turned to exploring 
the biological make up of stem cells and their locations in the human body. 
A vast amount of research has been focused on pinpointing the capacities of 
stem cells - where they originate, how they maintain their potency, their ability to 
seemingly divide indefinitely and more  
Stem cells have been described as a class of undifferentiated cells of a multi-
cellular organism which have the potential to give rise to indefinitely more cells of 
the same type.  From the initial (stem) cells, other more complex kinds of cells 
begin to form through a process known as cell differentiation. Cell differentiation 
is a biological process through which "every cell, whether the liver, heart, or brain, 
takes on its role by specialising into a particular cell type, with a characteristic 
shape and function" (3). The most important aspect of stem cells is that these are 
the only cells in multi-cellular organisms which have the capability to differentiate 
into many, if not any, cell types.  
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Thus the two crucial attributes of stem cells are:  
1. Their ability to proliferate as well as  
2. Their potential to differentiate (4) 
While all stem cells share these attributes, it has been found that not all stem 
cells possess the same capacity or potency to proliferate and differentiate.  
2.1 The Different Kinds of Stem Cells 
 
Closely linked to the regeneration and production of new cells, is the type of stem 
cell which is producing the new cells. While each kind of stem cell possesses the 
ability to produce specialised cells, in most types the differentiation which is 
possible is quite limited. The three main categories of stem cells have been 
defined based on their ability to differentiate and can be described as follows: 
1. Totipotent Stem Cells 
These are stem cells which possess the ability to differentiate into all the 
different kinds of cells within the human body, and so are able to give rise 
to an entire organism. These would be the same cells from which embryos 
develop; they are produced during the process of fertilization and 
embryogenesis. 
 
2. Pluripotent Stem Cells 
This category of stem cells, while not able to regenerate or produce an entire 
organism, can indefinitely produce specialised cells for any part of the body. 
This category of stem cells originate as the inner cell mass within a blastocyst. 
 
3. Multipotent Stem Cells 
Multipotent stem cells refer to the group of stem cells which can give rise to a 
limited number of specialised cells within the body but only those of a closely 
related family of cells. These other types of cells which the multipotent stem 
cell produces are also limited in number.  
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Multipotent stem cells can be found in our bone marrow, for example, where 
different types of blood cells are produced but where the potency and amount 
begin to fade with time.  
2.2 Where are Stem Cells found? 
 
As described above there are different types of stem cells, which originate in 
different locations within the body of a multi-cellular being. Stem cells are most 
commonly defined by the stage of development of the organism from which they 
are derived. Due to this scientists generally prefer to work with embryonic, foetal 
and adult stem cells, depending on the source of these cells (3).  
Figure 1: The Formation of Embryonic Stem Cells (5) 
 
 
1. Embryonic Stem Cells (ESCs) 
Stem cells which originate from an embryo are known as Embryonic Stem 
Cells. These cells are formed and extracted within the first 4 to 5 days after 
fertilization has occurred. Depending on how soon the stem cells are taken, 
the resulting potency and ability to differentiate of the stem cells changes from 
totipotency to pluripotency. This will be explored in more detail in the next 
chapter.  
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Embryonic stem cells have been the centre of the majority of scientific and 
medical research since the 1980s (2),when the first embryonic stem cell line 
was created from a hamster. ESCs have since been hailed as the golden 
standard for all stem cells, as these particular stem cells are, to date, the most 
potent and possess the ability to differentiate indefinitely into all types of cells.  
 
Essential to the debate concerning stem cells, indeed of paramount 
importance to many who oppose using embryonic stem cells, is that through 
the procedure of acquiring these pluripotent stem cells the embryo is 
"disaggregated and destroyed" (6). 
 
2. Foetal Stem Cells 
These kinds of stem cells are derived from the tissue of aborted foetuses 
within the time frame of five to nine weeks post-fertilization (3). These kinds 
of stem cells are described as being multipotent. However it has been found 
in some cases that they are able to differentiate into a wider variety of cells 
than their adult counterparts (3).  
 
There have also been some instances where foetal stem cells act in a 
pluripotent manner, such as when they are derived from foetal reproductive 
tissue. According to the Irish Council for Bioethics' Stem Cell Report, 
"scientists have discovered stem cells in amniotic fluid, which surrounds the 
unborn foetus" (3) and which are pluripotent in nature. 
 
3. Adult Stem Cells 
It is presumed by many that these kinds of stem cells relate only to those over 
a certain age - this is not the case. Adult stem cells refer to stem cells obtained 
from babies, children, adults, and "even in umbilical cord blood" (3). These 
stem cells can be obtained from numerous locations around the human body; 
bone marrow, skin, the brain, blood, eyes, liver, and hair. Due to the fact that 
these stem cells have already differentiated to some extent during the 
organism's life-span, their ability to become a multitude of cells is limited. As 
such, adult stem cells are described as being multipotent in their ability to 
differentiate.  
 
24 
 
4. Induced Pluripotent Stem Cells 
An important point to note here would be that in the last decade research into 
the differentiating ability of adult stem cells has been extensive due to the 
pressure placed on researchers to find a more ethical way of obtaining 
pluripotent stem cells - namely, a method whereby no loss of life or even the 
potential loss of life could occur.  
 
The first glimpse of the potential of adult stem cells was not recognised until 
2006, when Shinya Yamanaka and his team managed to reprogram adult 
stem cells into pluripotent stem cells, which as outlined above equates these 
new stem cells to embryonic stem cells. This reprogramming was achieved 
through the addition of four specific transcription factors which altered the 
biological programming of the adult cell, thereby causing it to act as if it were 
an embryonic stem cell (7). These newly reprogrammed cells are now known 
as Induced Pluripotent Stem Cells and will be explored in greater detail in 
the following chapters. 
2.3 The Possibilities of Stem Cell Therapies 
 
"There is nearly universal agreement in the scientific community that stem cell 
research should contribute to the alleviation of human suffering and disease" (8). 
The possibilities of stem cell research are at times awe-inspiring, with promises 
of future applications which will cure all kinds of ailments, injuries, diseases, as 
well as other social constructs such as old age (interview source). While 
controversy surrounds the method of obtaining embryonic stem cells, it is vital for 
the continuation of research into this important area of medical science, that the 
possibilities which stem cells could offer are thoroughly explored and 
communicated clearly to inform public opinion. 
1. Understanding Cells 
As highlighted above, stem cells are the originating cells of all humans. It is 
from these few cells whereby a complete organism comes into being through 
the process of cell differentiation.  
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Cell differentiation has eluded the scientific grasp for decades, but with the 
advent of stem cell lines research has taken on a new edge.  
 
This is because diseases such as cancer or conditions arising from birth 
defects are thought to occur because of problems in the differentiation 
process, and so "an understanding of the development that happens in normal 
cells will help scientists treat the developmental errors that can occur" in cells 
effects by disease (2).  
 
Researchers are now able to efficiently produce all of the different kinds of 
body cells which make up the human organism - neurons, skin cells, blood 
cells, muscle, bone etc. With this abundance of material, those who were once 
hampered by lack of resources can now attempt to fully explore the functions 
of these cells, how they differentiate, and their applications.   
 
2. Treatment of Disease 
Stem cell research possesses the potential to discover cures and effective 
targeted treatments for some of the worst degenerative and debilitating 
diseases, as well as permanent injuries. Researchers are now able to 
developing stem cell lines with particular mutations in order to experiment with 
alternative cures. The main diseases which have captured the focus of stem 
cell research are heart disease, cancer, diabetes, Parkinson's, and 
Alzheimer's (2). It is hoped that stem cell research will aid the search for 
clinical cures or treatments for many, if not all, of the life threatening diseases 
currently known to exist. 
 
3. Patient Specific Therapy  
One of the main problems associated with tissue transplants or organ 
donation whereby the donated organ is rejected by the receiving body. This 
is called an immune reaction, whereby the patient's body attacks the new 
cells, which are recognised as foreign. This recognition is due to the antigens 
on the new cells' surfaces; "Antigens, which are present on the surface of 
cells, are the signals by which the immune system recognises external cells 
and proceeds to reject them" (3).  
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It is believed that embryonic stem cells "have an advantage over stem cells 
from the adult body because they express less antigen molecules on their cell 
surface" (3), and thus may escape immune rejection.  
 
The difference with adult stem cells is that these can potentially be taken from 
the same body which they are then injected into, which would not produce as 
much of an immune response and rejection. This approach is referred to as 
'patient specific therapy' (3). 
 
Bearing this therapy in mind, it is believed by some that "the derivation of 
embryonic stem cells represents a major advance towards the development 
of personalized medicine" (4). Theoretically every person on the planet would 
have a personal bank of stem cells, ready to be utilised for any kind of medical 
emergency.   
 
4. Renewable Resource of Tissue and Organs 
"Today, donated tissues and organs are often used to replace damaged 
tissue, but the need for transplantable tissues and organs outweighs the 
available supply" (7).Stem cells hold the potential to offer a renewable source 
of both tissue and organs. If this were to come to pass, the social 
consequences could be enormous, ranging from the eradication of the black 
market in organ procurement commerce to a reduction in patient death rates 
which are due to lack of  organ or tissue donations.  
 
"For those suffering from serious diseases, stem cells offer hope for effective 
treatment or perhaps even a reversal of the disease," or of age itself (2). However, 
as exciting as these applications are, they are still in the primary stages of their 
full realization and a lot more intensive research is required.  
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3. Introduction to Embryonic Stem Cells 
 
This chapter will be dedicated to thoroughly exploring the diverse opinions which 
have shaped and informed the embryonic stem cell debate as well as obtaining 
a better understanding of ESC history. This foundation will establish the ethical 
and legal issues which will then be explored in further detail within chapters four 
and five as well as receive critical commentary therein.  
3.1 History and Discovery of Embryonic Stem Cells  
 
Built upon decades of extensive research, the history and trajectory of embryonic 
stem cells is tremendous. Stem cell research was first reported in attempts to 
fertilise mammalian eggs outside the body in 1878 (9). Subsequently the rapid 
evolution in medical understanding and knowledge contributed to ongoing stem 
cell research, development and refinement of techniques and processess. A time 
line - Appendix 1 : U.S. Department of Health and Services, is  a useful reference 
point for the remainder of this paper (9). 
Embryonic stem cells are stem cells which originate from an embryo. Intricately 
linked to ethical and legal issues in relation to this kind of medical research, are 
the different stages of development, whereby ESCs can be obtained. Although 
many would assume that such biological detail is superfluous, it will become 
apparent through later exegesis of the ethical and legal issues that these minute 
details have been the main, if not deciding, influence on the many differing 
opinions in relation to the embryonic stem cell debate.  
Starting from just before conception, there exists two separate sex cells, an ovum 
produced by the female human and a sperm which is produced by the male 
human. Each of these sex cells contains 23 chromosomes. For reference 
purposes, every single cell in the human body for any human being, apart from 
these sex cells, contains 46 chromosomes. This is our biological make up.  
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Once these two sex cells fuse through a process known as fertilization, a zygote 
is formed which now comprises both sets of 23 chromosomes, thereby 46 
chromosomes in total; "the full complement of the human genome" (3). Enough 
necessary to proceed with embryogenesis. (See figure 2) 
Figure 2: The Process of Fertilisation (5) 
 
 
 
 
 
 
 
 
According to the 2012 Irish Council of Bioethics' Stem Cell Report (3), " 
Embryogenesis spans from the end of fertilisation (zygote stage) until the end of 
the eighth week of development, after which the developing human is referred to 
as a foetus" (3). It is important to note here that the labels which are used to 
denote the different stages of development of the zygote are not entirely set in 
stone; It has been argued that terms such as 'pre-embryo', which is usually 
employed to describe the zygote during the first 14 days of embryogenesis, is an 
attempt to distance the researchers from the possibility that they are researching 
on living humans.  This use and manipulation of language will be explored further.  
There are four main stages of embryogenesis which are essential to the ESC 
debate; the formation of the morula, the formation of the blastocyst, implantation, 
and gastrulation.  
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1. The Formation of the Morula 
Starting with the single cell zygote, a process known as Mitosis begins whereby 
the cell starts to divide itself into two cells, which then divide into four cells, and 
so forth. These first few cells of the embryo are described as Totipotent Stem 
Cells, stem cells which possess the ability to differentiate into all the different 
kinds of cells within the human body, and so are able to give rise to an entire 
organism. If the cell group splits at this stage identical twins or triplets can begin 
to develop (8). Some view this as the defining moment in the life of the embryo, 
believing that this is the point where the life of the individual truly begins.   Merely 
four days after fertilization occurred, the cells have divided four or five times 
resulting in the formation of a "solid ball of 16-32 cells called the Morula" (3).  
2. The Formation of the Blastocyst 
Over the course of the next day, the Morula begins to hollow out and fill with fluid. 
These additional characteristics transform it into what is known as the Blastocyst. 
"The embryo will now develop from a specific cluster of blastocyst cells referred 
to as the inner cell mass, embryonic disc or embryoblast" (3). These cells are 
Pluripotent Stem Cells, and are able to give rise to all the necessary cell types 
of the developing embryo. It is usually at this stage of development whereby 
researchers attempt to retrieve the Pluripotent Stem Cells by isolating the 
blastocyst and extracting its inner cell mass. It is important to understand that 
through this process of extraction, the embryo cannot continue with 
embryogenesis; as some would affirm, it is damaged and irrevocably destroyed. 
Figure 3: Formation of the Blastocyst (5) 
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3. Implantation 
Should Blastomere extraction not take place, embryogenesis continues 
uninterrupted; While the zygote has been developing from a Morula into a 
Blastocyst, it has been travelling from the fallopian tubes of the female 
reproductive system and, after about 5-6 days since fertilisation, it has reached 
the uterus and begins to attach to the lining of the uterus i.e. implantation takes 
place. This process "should be complete by day 12 (usually day 8-10)" (3). Once 
this process is complete, the embryo continues to develop using the maternal 
blood supply.  
4. Gastrulation 
Two weeks after fertilization, the cells of the inner cell mass of the blastocyst 
begin to form into distinct cell types which will form the embryo. It is at this stage 
that the embryo is now termed a "Gastrula" and the possibility of twinning is no 
longer possible. Essential to the debate concerning ESC research is that it is at 
this point (usually day 14) where the Primitive Streak forms; "This structure 
orients the early embryo, defining its head and tail, and can be described as the 
precursor of the embryo's vertebral column" (3).  
Although the latter two stages do not appear to pertain directly to embryonic stem 
cell research, they are of utmost importance when debating the controversial 
ethical issue of when true human life begins for a developing embryo/foetus. For 
some it may be the case that life begins from the moment of conception, whereas 
for others this decision is not as straightforward as it may seem.  
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3.2 Alternative Methods of Obtaining Human Embryonic Stem Cells 
 
Embryonic stem cells have been the centre of nearly all stem cell research since 
the early 1980s due to their pluripotency and ability to differentiate into all the 
cells of the human body. The moral issue raised by a multitude of philosophers, 
scientists and researchers alike ((8),(4),(3), (10), (11), (12)) of the need to destroy 
an embryo to retrieve embryonic stem cells has led to significant pressure to find 
morally acceptable alternative sources for such stem cells. New alternative 
methods of creating or obtaining embryonic-like stem cells are currently being 
explored.  
IVF - In Vitro Surplus / Supernumery IVF Embryos 
Researchers can obtain surplus embryos from IVF treatments where couples or 
individuals undergoing this treatment choose to donate them to stem cell 
research. In vitro fertilization can be described as a process whereby a couple 
(or an individual) for some reason or another cannot become pregnant or cannot 
bring a foetus to term through natural methods, and so need external help to do 
so. The female goes through hormone treatment which stimulates her ovaries 
and causes them to produce an abundance of eggs which are extracted and, in 
a laboratory culture dish, are combined with the sperm specimen which the 
respective male participant has provided. The joint ovum and sperm are now 
known as zygotes because fertilization has occurred. Usually two zygotes are 
then placed within the female's uterus with the hope that at least one will implant 
i.e. attach to the uterus. The remaining zygotes are usually cryo-preserved 
(frozen) for the couple, should they wish to conceive again in the future.  
The reason that this particular method of conception is well known as a source of 
embryonic stem cells is because of the multitude of spare zygotes which have 
been stored by these couples. These are known as Supernumery IVF Embryos 
(3) and provide stem cell researchers with an alternative source of embryos 
needed to extract Embryonic Stem Cells.  
Controversy still surrounds this procedure, as many argue that even though the 
embryo exists outside of the uterus it is still alive and thus using these embryos 
is just as immoral as using embryos conceived through natural methods.  
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This argument is explored through the Potentiality Argument section, whereby 
the consequentialist understanding of the embryo's life is determinant of the 
degree of moral status which it acquires; thus in the case of embryos created 
specifically for research purposes (and which will never be born or develop past 
a certain point) no moral status is ascribed (3, 13).  
SCNT - Somatic Cell Nuclear Transfer 
Also known as "therapeutic cloning" (8), SCNT "was first used 40 years ago in 
research on tadpoles and frogs" (3) whereby scientists were attempting to 
understand gene expression and "whether genes necessary for development 
could be switched back on in differentiated adult cells in which they had long 
ceased to function" (3). Their conclusion was affirmative; that SCNT "effectively 
reset the gene expression of a differentiated somatic cell to a state consistent 
with embryonic development" (3). 
Figure 4: Somatic Cell Nuclear Transfer (5) 
 
Succinctly, SCNT is a procedure whereby a "technician removes the nucleus of 
a somatic cell and inserts it into an enucleated oocyte termed a cytoplast, where 
the egg cytoplasm reprograms the transferred donor nucleus" (8) into thinking 
and acting as if it is an embryonic cell.  
 Somatic Cell 
 Somatic Cell 
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This "new embryonic cell" then undergoes normal cell mitosis (which, as the 
nucleus now believes it is an embryonic cell, may be called embryogenesis) 
which culminates in a blastocyst forming, and thus an inner cell mass which can 
be harnessed for pluripotent stem cells. See Figure 3. A central ethical concern 
at this stage is the amount of eggs which will be needed for such a method to be 
used worldwide. This topic is further explored with reference to the 
commercialisation of human eggs and embryos.  
ANT - Altered Nuclear Transfer 
Altered Nuclear Transfer was proposed by William Hurlbut in 2005. It is an 
alternative approach to therapeutic cloning, with which Hurlbut attempted to 
bypass the ethical controversies of producing cloned human embryos to obtain 
patient specific embryonic stem cells (3). The technique is exactly the same as 
SCNT, with the only difference being that a gene which is necessary for embryo 
implantation is genetically altered in the donor nucleus before it is transferred into 
the egg cytoplasm (3). This genetic modification is achieved using a technique 
called RNA interference whereby researchers disrupt a gene called Cdx2, which 
enables an embryo to grow a placenta (3).  
Once the remainder of the SCNT process is completed and the embryo begins 
to form, due to the genetic modification it will be unable to develop a placenta and 
thus will be unable to implant. Theoretically it can be argued that as the embryo 
cannot, indeed will never be able to, implant and naturally develop into a human 
then no loss of potential life occurs when the embryonic stem cells are harvested. 
As Hurlbut asserts, a human embryo created by ANT would be a biological entity 
“that lacks the attributes and capacity of the human embryo” (3) and thus cannot 
be conceived of as being a potential human. In the eyes of the author it appears 
that Hurlbut does not take into account that this kind of deliberate debilitation of 
what could be a viable embryo is just as morally wrong as using viable embryos 
to harness stem cells in the first place.  The reasoning for this is explored further 
on.  
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The main scientific disadvantage for this alternative source of embryonic stem 
cells is that while it has been achieved successfully through research studies on 
mice (3), scientists have yet to fully evaluate the impact this genetic modification 
has on potential stem cell development. As well as this, researchers are not fully 
convinced that Cdx2 is the only gene which effects embryo placenta development 
(3).  
Single Cell Blastomere Extraction 
Modelled on PGD (Pre-implantation Genetic Diagnosis) methods, single cell 
Blastomere extraction refers to the process of taking a single cell from an eight 
cell IVF embryo and using it to establish a stem cell line. This process is similar 
to PGD in the way that it is at exactly the same stage of development whereby a 
single cell is extracted from the eight celled embryo. The only difference is that in 
the case of PGD this cell is tested for genetic abnormalities which may inform the 
parents about the embryo's genetic make-up. The leading advantage of this 
method is that the remaining seven cell embryo could still potentially be used to 
treat infertility (3). Tested on mice, whereby the same procedure occurred, the 
remaining seven celled embryos were transferred to the surrogate mother's 
womb and were carried to term, with no discernible defects (3). Although this new 
method seems promising, given the relatively young age of PGD long term 
studies of its implications have yet to be conducted and so single cell blastomere 
extraction seems less likely to be the chosen alternative until such research is 
concluded (3).  
A major ethical issue for this alternative method of obtaining human embryonic 
stem cells is that the cell which is extracted from the eight cell stage might still 
possess the potential of a Totipotent cell; thereby possessing the ability to 
become a viable human embryo itself (3). Although this has only been established 
in rabbits and sheep, the possibility that a human could potentially form from this 
single cell has been levelled with the same charge which the method was 
attempting to bypass; namely, that destroying an organism (the Totipotent cell) 
which could potentially become a human (or is a human depending on the view 
given) is highly immoral (3).  
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Somatic Cell De-Differentiation 
One of the main methods for obtaining human embryonic stem cells is through 
cell de-differentiation. Where cell differentiation refers to the process by which 
cells become specialized to a particular role within the human body, cell de-
differentiation refers to the complete opposite; namely, that the cells revert to a 
less specialized role. As this method of obtaining stem cells does not require the 
destruction of a human embryo, a strong argument can be made proposing this 
line of research as opposed to that of human embryonic stem cell research, as it 
appears to circumvent many of the ethical and legal challenges posed by the 
latter.  
Whether this alternative approach actually does help resolve these issues is the 
question at the forefront of this thesis. Prior to grappling with the sensitive ethical 
and legal issues which human embryonic stem cell research conjures, an in-
depth understanding of the leading somatic cell de-differentiation technique 
needs to be explored; namely, Induced Pluripotent Stem Cell research. 
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4. Introduction to Induced Pluripotent Stem Cells 
 
While human embryonic stem cell research continued to face ethical and legal 
barriers, researchers from the medical profession sought a more ethically 
acceptable means of obtaining stem cells, in particular stem cells which could 
replicate the efficiency and potency of human embryonic stem cells. Prior to the 
medical breakthrough by which iPS cells were produced, the preferred method of 
obtaining human embryo-like stem cells without major ethical or legal implications 
was SCNT. That said, SCNT poses its own economical and ethical problems as 
it requires a great supply of non-fertilized human eggs, which will receive further 
analysis in chapter four. Thus, the search for a better means of procuring human 
embryonic stem cells without the dubious ethical and legal complications 
continued. Based on years of human embryonic stem cell research as well as 
extensive analysis into the differential process of human body cells, a 
breakthrough occurred within the area of somatic cell de-differentiation.  
4.1 Discovery of Induced Pluripotent Stem Cells  
 
In 1962, John B. Gurdon demonstrated that the nucleus from a differentiated frog 
intestinal epithelial cell can generate a fully functional tadpole via transplantation 
to an enucleated egg. Gurdon used somatic cell nuclear transfer (SCNT) as a 
method to understand reprogramming and how cells change in specialization. He 
concluded that differentiated somatic cell nuclei had the potential to revert to 
pluripotency. This paradigm shift in the understanding of the differential capacity 
of cells stimulated the extensive research into de-differentiating human body 
cells. 
Just over half a century later, in 2007, three research groups, based in Japan and 
the United States, confirmed a new method of obtaining stem cells which 
possessed similar efficacy and potency as embryonic stem cells (3, 14). Of the 
three researcher groups, Shinya Yamanaka and his team, in Kyoto University 
Japan, were the first to generate these new cells using mouse fibroblasts in 2006.  
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The following year, in November 2007, Yamanaka and his team were able to 
apply the experimental new method to human somatic cells which resulted in the 
successful production of human embryonic-like stem cells (3). 
Meanwhile, in the United States, at around the same time, James Thomson at 
University of Wisconsin-Madison achieved the same result helping to validate the 
results achieved by the Japanese team (15).   
4.2 Methods of Creating Induced Pluripotent Stem Cells 
 
The methods followed by each of the Yamanaka and Thomson research groups 
are quite similar, in that the general approach specified that three or four specific 
human genes, also known as transcription factors, found previously to be 
important for development could be expressed within the somatic cells and in turn 
coax them into an embryonic cell-like state (3). Transcription factors are proteins 
involved in the process of converting, or transcribing, DNA into RNA within a cell. 
These factors regulate the gene expression within cells by reading and 
interpreting the genetic 'blueprint' within the cell's DNA, thereby directly 
influencing the role and differentiation capacity of the cell.  
To fully appreciate the exhaustive measures that were applied to discovering 
these factors, a brief exploration of the gruelling process of elimination employed 
by Yamanaka and his team must be acknowledged. Starting with a list of over 
100 possible transcription factors, unsure of whether these factors acted alone or 
need to be employed in conjunction with another specific factor or multiple 
factors, Yamanaka began the process of whittling down the list of over one million 
combinations which could lead to cell de-differentiation (7). Through the use of a 
computer program he was able to identify 24 of the most likely factors able to 
stimulate de-differentiation. Through years of research, Yamanaka and his team 
were able to identify four transcription factors which normally only act together 
within an embryonic stem cell; Oct3/4, Sox2, Klf4, and c-Myc. These four factors 
were then placed into a skin cell. In a process which was not fully understood at 
the time and is still being explored, the chromosomes within the skin cell began 
to unravel.  
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By doing so, the factors which were introduced to the cell could attach to the 
genes of the cell and overwhelmed the competing message from the skin genes, 
thereby tricking the cell into believing it was in an embryonic environment. As 
these pre-programmed cells replicated, they became more like embryonic stem 
cells, until they were indistinguishable from them.   
Figure 5: Production of Induced Pluripotent Stem Cells (5) 
 
Although both Yamanaka and Thomson applied similar methodology in achieving 
their aims, both teams utilized different proteins/genes and viral systems to 
attempt to de-differentiate the human fibroblasts. These systems were needed to 
insert the transcription factors into the cell. Where on the one hand Yamanaka 
employed four pivotal human genes, namely Oct3/4, Sox2, Klf4, and c-Myc, 
through a retroviral system.  Thomson and his team, on the other hand, chose to 
apply OCT4, SOX2, NANOG, and  LIN28, using a lentiviral system. While it can 
be argued that both combinations of factors achieve a similar result, the process 
has yet to be perfected and the use of each individual factor may produce 
unwanted side effects in the resulting stem cell (16).  
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4.3 Possibilities of Induced Pluripotent Stem Cells 
 
Aside from the possibility that induced pluripotent stem cells could limit the need 
for embryonic stem cells, the consequences of producing induced pluripotent 
stem cells are far reaching and positive. Due to the fact that they are able to give 
rise to all three germ layers of the developing embryo, I.e. being pluripotent in 
nature, induced pluripotent stem cells appear to alleviate many medical problems 
associated specifically with supply shortages in many areas. Such as, organ 
donation, blood donations, and even reproductive cell donations (4). Coupled 
with their potential to proliferate infinitely, iPS cells seem almost miraculous in 
their possible applications.   
Through the discovery of Park et al that human cells from various sources are 
able to be reprogrammed (3, 8), cellular de-differentiation holds much potential 
and promise for developing patient specific stem cells (8). Such specifically 
designed stem cells may be utilized to treat patients individually, using their own 
somatic skin cells as the starting point of producing their own personal stem cells. 
By doing this, it has been proposed that immune-rejection of stem cells could be 
very much reduced, as the stem cells will possess similar, if not identical, genetic 
information as the host organism as well as similar surface antigens which are 
the primary trigger for immune rejection (11). This medical technology could 
potentially revolutionize the healthcare industry worldwide, not only through the 
use of a patient's specific stem cells but also through the ease of obtaining these 
stem cells through the patient's own somatic cells. Following treatment the stem 
cell line may be stored in a stem cell bank for easy access in the future.  
Not only that, but the production of disease specific cells through the production 
of stem cells will greatly enhance the speed and precision of researchers 
attempting to identify and treat some of the world's most degenerating diseases, 
for example Alzheimer's and Parkinson's Disease (4). A particular setback in 
relation to this field of research is the inability of researchers to apply new found 
discoveries to human patients with the disease. With the introduction of disease 
specific stem cells, researchers will have an abundance of infected human cells 
with which new cures or treatments may be tested upon. This aspect of induced 
pluripotent stem cells is a driving force behind the research taking place.  
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Not only will this application eliminate the need to test certain cures or treatments 
on purposefully infected animals, but it may speed up the process of releasing 
said cures to the human public, as it may reduce the amount of time needed for 
human clinical trials.  
4.4 Problems Associated with the Creation of iPS Cells 
 
While the newly reprogrammed cells appear similar to embryonic stem cells in 
terms of their morphology, efficiency, and potency potential (3), this new method 
poses its own problems.  
Using ESCs as the “Golden Standard” of what pluripotent cells should be capable 
of, researchers and critics of induced pluripotent stem cell research have been 
able to highlight areas of significant concern within the methods and 
consequences of creating induced pluripotent stem cells.  
Although the main contributory transcription factors needed to create induced 
pluripotent stem cells have been identified, little is known concerning any future 
repercussions of their employment. Of primary import is that expression of these 
factors within the fibroblast could possibly lead to tumour formation (3). As well 
as this, the efficiency of converting somatic cells to iPS cells is still relatively low, 
meaning that while the possibilities seem endless, their achievement might be 
further away than anticipated (17). 
Until safer and more stabilized means of inducing pluripotency is discovered, 
human clinical trials which are necessary prior to approval for real-world 
application will not be allowed to take place and thus all the possible advantages 
of induced pluripotent research, including the possibility of an ethical alternative 
method of creating human embryonic stem cells, will remain unachievable.   
As important as these biological and scientific issues are, the question of this 
thesis remains: do induced pluripotent stem cells resolve the ethical and legal 
dilemmas posed by embryonic stem cell research? The following chapters seek 
to analyze and compare both embryonic and induced pluripotent stem cells in an 
effort to offer an answer to this question. Specific attention will be paid to the 
ethical and legal foundational issues of embryonic stem cells, which iPS cell 
research is seeking to overcome through its employment.  
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5. Ethical Issues of Human Embryonic Stem Cells 
 
The central line of inquiry of this thesis is whether induced pluripotent stem cells 
are truly able to alleviate the ethical and legal dilemmas posed by current human 
embryonic stem cell research methods. In order to do this accurately, the central 
ethical and legal issues of human embryonic stem cells which induced pluripotent 
stem cells claim to resolve require analysis. This chapter will focus on the ethical 
issues of human embryonic stem cells.  
5.1 Where Does Life Begin? 
 
Using human embryonic stem cells to further medical knowledge is a leading 
issue within this debate. This is due to the fact that through the method of 
obtaining human embryonic stem cells from the blastocyst, the embryo is 
destroyed. Whilst proponents who are interested in furthering scientific 
knowledge accept this with little (it seems) moral question, opponents find it 
difficult to grapple with. To them, it is evil and immoral, and they fervently oppose 
it. Due to this, the science of stem cells has been drawn into the highly divisive 
debates concerning the interpretation of life. These debates have existed within 
the legal and political spheres for the last three decades (18).  
This part of the human embryonic stem cell controversy can be succinctly 
described as a debate concerning the point at which a zygote, embryo or foetus 
(depending on the opinion given), gains moral status as a human being - thus, 
becoming or being endowed with all the social endowments and protections this 
affords, for example, the right to life, dignity, personhood etc. Through 
examination of the relevant literature and research, it becomes apparent that 
there are three main categories which encompass the general popular opinions 
in relation to this issue: (18, 19) 
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Table 1: Categories of When Personhood is Ascribed 
 
Certain factors and influences from the social and cultural aspects of individuals' 
lives have helped shape the above understandings of when or whether an 
embryo deserves certain rights and protections. A deeper examination of these 
factors will help illuminate the reasons as to why this aspect of the stem cell 
debate has such considerable implications.  
 
 
•Advocates from this group believe that from the moment of
conception / fetilization the embryo "is a new human being or
individual with all the rights and legal and moral status of fully
born persons".
•These groups view destruction of embryos, including abortion,
as murder, "as a sacrafice of the weakest amongs us for the
interests of others" .
•They continue to uphold their sanctity of life arguement, even
where supernumery embryos, which are to be discarded
anyway, could be used for research purposes.
Full Status From 
Conception
•The gradualist approach is summarised as one which "is
somewhere between [the other two] and holds that the
embryo is human tissue with the potential for human life, and
thus deserves respect".
•This group has multiple understandings of the point at which
the embryo becomes endowed with personhood. This is due
to cultural, religious and social reasons which are highlighted
below.
•The gradualist group has also been described as those who
"believe that [embryos] gradually gain moral status as they
develop" (rte.ie/science), and can also believe the embryo to
be deserving of special limited rights.
Gradualist
•Proponents from this category view the "embryo as too
rudimentaty in development to have interests or rights, and
thus [believe] that they should not be protected at the cost of
legitimate and important scientific research".
•For this group, no real sacrafice is taking place as the embryo is
not alive and so does not theoretically 'lose out' on life or
dignity.
•Those who view human embryonic stem cell research with this
perception of early embryos, do not find it difficult, indeed can
believe it to be a moral obligation to use embryos which would
otherwise be aborted or discarded for research purposes.
No Status
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Religious Influences 
Religion plays a major role in influencing the moral codes employed by 
individuals; for centuries it has been the moral compass which has denounced 
immoral acts and upheld, even encouraged, basic rights at times when no other 
institution did. For example, the Golden Rule , do unto others as you would have 
them do unto you,  has formed a solid moral basis for many, if not all, religions in 
some way or form. As a social construct, it has given voice to the innate moral 
capacity which humanity possesses with regards to maintaining and promoting 
life.  
Generally those of the first category, Full Status from Conception, are active 
members of their religious community and faith. It is usually this group who view 
all human bodies, no matter what the circumstances, be it age, social status, race, 
or biological development, to be of equal value and fully endowed with human 
rights. 
This perception of personhood and moral status closely mirrors the way which 
conservative Catholicism views the debate on when life begins (3). For the 
Roman Catholic body, each individual is to be seen as an image of God himself, 
one who must always be treated as an end in himself or herself, not merely as a 
means to other ends (20). A paper written and published by the Pontifical 
Academy for Life (21), found on the Vatican's website, explores the Catholic 
perspective of stem cell research, and succinctly summarises (with reference to 
both the Evangelium Vitae and the Donum Vitae) that: 
"The Church has always taught and continues to teach that the result of human 
procreation, from the first moment of its existence, must be guaranteed that 
unconditional respect which is morally due to the human being in his or her totality 
and unity in body and spirit: The human being is to be respected and treated as 
a person from the moment of conception; and therefore from that same moment 
his rights as a person must be recognized, among which in the first place is the 
inviolable right of every innocent human being to life" (21). 
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Dating to the 17th Century, when Pope Pius IX dropped the distinction between 
the foetus inanimatus and the foetus animatus, the Catholic church has 
maintained its faith in the sanctity of life; namely that from the moment of 
conception, an embryo should be accorded full moral status (3). There exist other 
bodies which support this view of the embryo, such as Eastern Orthodox 
Christians (3).  
Another main religious body, namely Islam, holds quite contrary views to that of 
Catholicism. Perhaps not quite in the Gradualist group, the Islamic faith stands 
somewhere along the border between full rights for the unborn and advocating 
the necessity of human embryonic stem cell research, through which an early 
embryo is destroyed. It has been advocated by Islamic scholars that it is their 
religious duty to pursue and consider medical research which is directed towards 
discovering new treatments which could alleviate disease or improve health (19). 
For some Muslims the possibility of using embryos in a therapeutic manner to 
save human life causes the act of human embryonic stem cell research to be 
seen as a collective religious obligation (fard kifaya) (19). 
Thus, stem cell research has been received with a more open mindset than other, 
more traditional and morally entrenched religions. Muslim scholars rely on 
independent judgement (ijtihad) of verses found in the Qur'an or the Hadith (a 
book of the sayings and actions of the Prophet Muhammad) when faced with a 
modern day development which has no precedent in these primary sources. 
Therefore where stem cells appear to jeopardise the life of an unborn child, the 
query is one of where life begins (although this formation of the ethical issue is 
not exclusive to Islam).  
Islamic scholars describe the development of the embryo in two phases; namely, 
biological and human. Through a process of ensoulment, which is believed to 
be God breathing the soul of the being into the foetus, the two phases are 
differentiated. Hence for Muslims, biological life starts at fertilization, but human 
life begins after ensoulment. The main question here is: when exactly does 
ensoulment take place? According to one verse in the Hadith, some scholars 
have identified the timing of ensoulment to take place when the embryo is 40 
days old.  
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Depending on the interpretation, this could be extended to 120 days as the verse 
could be understood as describing three 40 day periods which the embryo must 
go through prior to ensoulment.  
Interestingly enough, if one were to assume that ensoulment takes place on the 
120th day, this corresponds more or less with the majority of worldwide legislation 
concerning the cut-off point of carrying out an abortion; generally the cut off point 
for legal abortions is around the 14 - 18 week mark, which equates to the 98 - 
126 day mark. 
A more critical question related to the incorporation of religious influences into 
this debate would be: is it absolutely necessary to do this? Through the ages, the 
religious definitions of what it means to be a person have changed significantly 
based on the cultural perceptions and intellect of the times; Aristotle for example 
employed a dualistic view of the person - defining the person as a "rational 
animal", acknowledging that a human person is at the same time a material being 
as well as a spiritual one (22). This interpretation however is not the only one 
which has permeated religious history. Nearly each religion has its own 
perception of the relationship between a person and his/her soul, whether they 
entwine as one from the moment of conception or whether ensoulment, as is the 
case in Islam, occurs later on during embryogenesis. Due to this it is the view of 
the author that while religious interpretations may influence opinions concerning 
embryonic stem cell research, it must not be the authoritative guide on the 
permissibility of the act.  
Definitions and Interpretations 
 
Definitions and interpretations, coloured by cultural and personal experience, can 
often cloud our understanding of this complex topic. Due to the plethora of 
conflicting opinions attached to specific phrases or words, definitions within the 
stem cell debate have appeared elusive to say the least, and limited in their scope 
at the most.  
A central term which is often employed in this debate and which appears to lack 
a solid definition is that of 'person' or 'personhood'. Intimately linked with this term, 
are the attributes which define exactly what it refers to.  
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Philosophers John Locke and Thomas Aquinas believe that certain metaphysical 
attributes exist which may help to define whether an embryo is a person and thus 
deserving of protection and fundamental human rights (23, 24). They explore this 
throughout their works and theorise that only a human person may possess the 
fundamental capacities necessary to exhibit the essence of what it means to be 
a living human, demanding respect and possessing an innate dignity .In 
embryonic stem cell research, this idea of personhood is employed to both 
propose and oppose the destruction of the embryo for research purposes.  
At first this term seems to carry only the simplest definition, but a further 
exploration of the complex nature to which it refers will convey the degree to 
which it convolutes the stem cell debate. A central problem with the term "person" 
or "personhood", one which is shared with all other terms used within this debate, 
is that it appears to lack a clear and definitive explanation of what it refers to. 
Hence multiple interpretations of the term have been advocated in conjunction 
with the above categories of status i.e. depending on the opinionated group's 
perception of the embryo's moral status.  
As explored above, opponents of human embryonic stem cell research base their 
opposition on the fact that an embryo is a human person from the moment 
conception takes place; from this moment on the zygote or embryo possesses a 
moral status correlated with an innate human dignity and thus deserving of all the 
human rights which those of us who are already born enjoy. Those against human 
embryonic stem cell research affirm that it is because the embryo is a human 
person (thus deserving the same degree of human rights and protections) that no 
research should be conducted on it regardless of the outcome (7).Immanuel Kant 
is the oft-quoted philosopher with regards to this side of the argument. As part of 
his Groundwork of the Metaphysics of Morals (25), Kant proposes the Categorical 
Imperative, a moral law that is unconditional or absolute for all agents. While the 
scope of this thesis cannot possibly hope to explore the full theory behind this 
moral imperative, the third condition of the CI succinctly advocates the rationale 
of those opposed to human embryonic stem cells; "Act so that you treat humanity, 
whether in your own person or in that of another, always as an end and never as 
a means only" (25).  
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Peter Singer, an Australian utilitarian bioethicist, argues that this point may not 
be as persuasive as it is believed to be. He makes a strong case that the kind of 
species to which the embryo belongs, does not directly influence the morality of 
using the embryo for research purposes. Rather, he affirms that it is the type of 
being which has influence of this kind (26). Dismissing the assumption that just 
because one will be born human he/she deserves full moral recognition and 
status. Singer, (as well as other philosophers such as John Locke) have 
presented this argument in the light that in order for a being to be classified as a 
person, certain empirical and cognitive faculties need be possessed by these 
beings. Note the exclusion of the word human, as there are other possible beings 
which could also possess these faculties. These faculties, succinctly described 
by David de Grazia (27), include complex forms of consciousness such as 
autonomy, rationality, self-awareness of one's place in time, linguistic 
competence, morality and sociability (27).  Separately, Singer proposes 
characteristics which de Grazia either intentionally excludes, or has not 
considered; namely, consciousness and the capacity to experience suffering. For 
these philosophers the definition of personhood or the debate on whether an 
embryo is a person, depends on the embryo's ability and capacity to possess 
these cognitive and empirical characteristics of a person, whereas for Kant simply 
being human is enough to warrant the expectation of being treated with respect.  
This kind of bi-polar interpretation is not limited to the area of stem cell research; 
it occurs once more, for example, in the case of a coma patient; are we to define 
this patient as a person and respect his/her dignity and moral status as such, or 
are we authorised to decide on behalf of the patient concerning, for example, life-
altering decisions? Generally in such cases those who are believed to be able to 
advocate for the best interests of the patient are assigned as a proxy decision 
maker. However in the case of stem cell research, sometimes this is not possible, 
especially if the embryos are created through SCNT or are donated to science 
for research purposes. In these cases it appears as if it does not matter that the 
patient's (embryo's) rights are protected.  
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It seems to the author that this link has been overlooked to some extent within 
the stem cell debate and recommends that further exploration is employed to 
highlight any possible connections which may help inform the rights and/or 
understanding of the personhood of an embryo.  
Other terms exist which cause added confusion within the stem cell debate are 
those which are used to describe the different stages of embryonic development. 
While most people can agree that an embryo refers to an unborn human when it 
comes down to the bare details of zygote to blastocyst, blastocyst to foetus, 
foetus to embryo, embryo to baby etc. the boundary lines are harder to agree 
upon. Use of these terms, without proper definition can possibly lead to confusion 
within the discourse, exacerbating certain uninformed perceptions rather than 
defining clear and concise instruction.  
Disagreement on the definition of a person and when human life begins has 
fuelled the ethical controversy allowing research to be conducted on embryos 
under the age of two weeks. This refers to the employment of the term 'pre-
embryo'. According to Richard M. Doerflinger, textbooks of the late 1980s and 
some British Laws employed this term in order to differentiate between an early 
embryo of up to 14 days, and one of later development (20). This definition 
enabled the foundation for non-therapeutic research on embryos which were 
younger than two weeks but has since been openly dismissed and discarded 
(20). Recently this term has been rejected by the Human Embryo Research Panel 
who are advocates of research performed on embryos under two weeks of age, 
as well as the National Bioethics Advisory Commission who defined an embryo 
as "the developing organism from the time of fertilization" (NBAC 1997) (20). The 
author suggests that this might have been employed as a moral deterrent to 
pursuing embryonic stem cell research, as the term was arguably employed to 
distance researchers from what they were doing i.e. destroying an embryo. 
Indeed, one research paper which focused on the use of this term stated that the 
phrase ‘pre-embryo’ was a semantic manipulation aimed at depriving the early 
embryo of its fundamental biological characteristic of living human being (28). 
Perhaps this was the reason why the term was, according to Doerflinger, later 
discontinued and the time it denoted (from fertilization to 14 days old) 
incorporated into the meaning of early embryo (20). 
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From the perspective of a gradualist interpretation, it appears to be quite difficult 
to pinpoint an exact time at which an embryo or foetus gains recognition as a 
developed being deserving of human rights. Due to the direct proportionality 
assumed between the development of the embryo and the moral status which it 
possesses, there exist multiple stages of embryonic development whereby moral 
status may be endowed: 
1. One such stage would be at the formation of the Primitive Streak, at 
approximately day 14 whereby the embryo is oriented thus beginning the 
process of Gastrulation. Alongside this with the formation of the Primitive 
Streak, the possibility of twinning is no longer possible - at this point it is 
believed that the embryo is now described as a unique individual, rather 
than an entity which may become more than one being (3). This view begs 
the question: at which stage of development do twins or triplets become 
unique individuals? Is there a different point of ensoulment which possible 
takes place or are such individuals only able to become separate entities once 
they are outside of development and have experienced the world? 
 
2. Another possible stage which gradualists may agree upon would be the point 
at which the embryo implants into the mother's uterus (3). Occurring just 
before the formation of the Primitive Streak, implantation is a defining moment 
in the development of the embryo. It is through this biological connection that 
the embryo can receive nutrients needed to progress with the pregnancy. 
However this also causes one to pause; would a human necessarily need to 
be able to receive nourishment and convey signs of sustaining life to be 
defined as a person? If this were the case, then defining the ethical and legal 
rights relating to personhood of a coma patient, who also receives nutrition 
from an external source, would need to be re-evaluated.  
 
3. Two other main stages which may cause some to consider granting the 
embryo a degree of moral status would be the formation of the neural tube 
(around 18 days), i.e. the structure from which the brain and spinal cord form, 
and the onset of the foetal heartbeat (around 2 days) (3).  
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In a way, this could be correlated to the multiple definitions of death which 
exist currently; brain stem death, biological death, and legal death. The author 
argues that if it is possible for us to define a precise point of death, whereby 
a human loses personhood status (arguably), then by extension this may help 
with the identification of the point whereby a person acquires personhood 
status.  
With such a vast account conflicting definitions, it is difficult to pinpoint which one 
succinctly defines the point at which an embryo, which has been established as 
a living cell, can be afforded moral status or what kind of rights it is entitled to and 
when.  
Potentiality Argument of the Embryo 
 
The Potentiality Argument is employed mainly by opponents to human embryonic 
stem cell research. The essence of the argument is that even though an embryo, 
under 14 days of age, is unable to communicate or employ the necessary 
characteristics some people would state are required for moral status to be 
conveyed e.g. Aquinas and Locke (as explored above), the embryo has the 
potential to one day develop into a fully functional, rational, linguistic, social 
being, one fully deserving of moral status and the associated human rights and 
protections. The author suggests that this argument is a strong statement; why 
wait to endow moral status on a being which we know has the capability to 
develop into a human being? Assuming, of course, no outside interferences 
diminish or restrict this development. As outlined in the Irish Council of Bioethics' 
Stem Cell Report, even if embryos do not qualify for fully fledged personhood, 
the argument can be made that their potential to become human beings should 
affect the considerations given to their moral status (3).  
A central problem with this argument is that it can be applied to other situations 
and contexts which highlight its weaknesses. For example, many of us have the 
potential to become criminals, yet it would seem unreasonable to treat us as if we 
were unless we actually fulfil this potential (3). It has been argued that this is a 
serious logical flaw to the Potentiality Argument; that moral status is to be 
grounded on the actual properties of a being, not the potential which the being 
possesses (3).  
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If the latter were the case, it would be nearly impossible to afford any human 
being moral status or rights, based on the fact that we possess multitudes of 
potential to act or develop in any way we see fit. 
An aspect of the potentiality argument is one which takes into account the method 
through which an embryo is brought to term, or rather, not. The essence of this 
criticism is that embryos which develop in the womb ( in utero) possess more 
potential to develop into humans than do those developed in a laboratory culture 
dish (in vitro). The main discerning feature between the two is that in the latter 
case purposeful external interventions are needed for the embryo to reach its full 
potential. Many proponents of human embryonic stem cell research use this as a 
means to justify using embryos cultured in vitro for stem cell research, as their 
potential is to perish (8). Due to this, the author questions if this means that 
embryos created in vitro are without any kind of moral protections at all phases 
of development (as limited as it may be)? Is it possible to establish which embryos 
would have implanted or not, had they been given the chance? Once more it 
seems as if potential researchers may advocate this 'distinguishing feature' 
between in vitro and in utero as an effort to pacify their own moral misgivings for 
the acts they are performing.  
Due to the moral outcry, influenced by religious, political, and interpretive factors, 
which human embryonic stem cell research generated, scientists and medical 
researchers endeavoured to find a suitable alternative source of these stem cells. 
5.3 Social Issues of Alternative Sources of Human Embryonic Stem Cells 
 
While the search for alternative sources of human embryonic stem cells is both 
noble and ethical in its aim, when one takes time to assess the morality 
surrounding such practises, startling ethical controversies arise. It is these 
controversies which led to more pressure being placed upon the medical field to 
find a better, more ethical method of obtaining human embryonic stem cells for 
research purposes.  
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IVF - In Vitro Surplus / Supernumery IVF Embryos 
As highlighted above an alternative source of human embryonic stem cells lies 
within supernumery IVF embryos, or rather surplus embryos which are not 
implanted into the mother's uterus and which are not going to be stored for future 
use. Proponents of using these embryos for stem cell research employ both a 
consequentialist as well as a deontological view of why using these embryos is 
morally acceptable; their central argument is that these embryos are going to be 
discarded anyway i.e. regardless of whether or not researchers intervene, these 
embryos are going to be destroyed. Thus, consequentially the embryos meet the 
same fate, however in the scenario where a researcher is the cause of 'death' the 
embryo has in some way contributed towards scientific knowledge. This leads to 
the deontological argument, which is closely linked to the utilitarian thought (i.e. 
the greatest and best outcome for the most amount of people), whereby scientists 
and researchers feel as if it is their duty to research on these embryos in order 
that the embryos lives are not wasted and/or discarded like something which can 
be easily replaced, and whereby the larger part of society may benefit. This is 
proposed by Gene Outka who bases it on the "nothing is lost" principle; This 
principle was developed by Paul Ramsey who summarised that it may be justified 
to kill an innocent person if this person was going to die anyway and if this death 
will save other lives (3).  
By employing both a consequentialist and deontological defence for the use of 
IVF embryos, the author believes that a strong case has been made to quell the 
moral fears of opponents to this research. Although recourse to the 'nothing is 
lost' principle is arguable, as indeed something is lost, namely, an embryo. 
Opponents to this alternative method have a strong deontological viewpoint 
which conflicts with that of the researchers' vindications. For proponents of the 
embryo's innate right to life and all its associated protections, it is the action of 
purposeful destruction of the embryo which causes death that creates the ethical 
unease; i.e. it is the intent to destroy which causes the ethical objection.  
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That is not to say that the same groups advocate for the discarding of such 
embryos if they serve no purpose; rather, such groups have been known to 
propose that all embryos which are produced for assisted human reproductive 
purposes should be utilised (3). In such a case, the intent would always be that 
the embryo has a chance to develop (3). 
The philosophical question remains unanswered however; is the action of actively 
destroying the embryo for research purposes the ethical equivalent of discarding 
the embryo? The Irish Council found in its Stem Cell report that while the former 
appears morally more objectionable than the latter, the outcome is the same in 
both cases. Some have even argued that doing nothing, i.e. discarding viable 
embryos, is just as bad as committing the immoral act (3), thereby usually 
expanding on this point to advocate the 'Nothing is Lost' principle. In the current 
case, the author would be in agreement with the conclusion reached by the Irish 
Council for Bioethics, but would hold onto reservations concerning the 'nothing is 
lost' principle. 
SCNT -  Therapeutic Cloning vs. Reproductive Cloning 
Another alternative of obtaining human embryonic stem cells for research 
purposes would be by SCNT. As described above in chapter three, this process 
involves the insertion of a somatic cell’s nucleus into an enucleated egg cell. By 
doing this, the new cell begins to act as if it is an embryonic stem cell, somehow 
resetting the already differentiate nucleus to an undifferentiated state.  
While this new embryonic cell shares genetic information of the somatic cell, it is 
not a genetic clone. This is due to the cellular DNA which can be found in the 
Mitochondria of human cells (8). That said, the new cell could potentially possess 
enough similar genes to the supplying patient to ensure a limited possibility of 
immune-rejection (3).   
Through the employment of this method, researchers hope to be able to develop 
stem cell lines which could then be used therapeutically to treat patients 
specifically with their own stem cells. This research has been labelled as 
Therapeutic Cloning (in contrast to that of Reproductive Cloning) because the 
cloned embryo is made solely to obtain embryonic stem cells for research or 
therapy (3).  
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As exciting as this venture might be, scientists have yet to perfect this method 
with human tissue, despite a fraudulent claim by Hwang Woo Suk in 2004 (3) that 
he had managed to do so.  
While SCNT can be described as a form as asexual reproduction, which many 
organisms utilise, the new embryonic cell is never implanted into a womb, human 
or otherwise, and brought to term. Ethically speaking doing so would be perceived 
as being obscenely immoral and biologically wrong, as this would change the 
exercise from therapeutic cloning, where patient specific stem cells are being 
harnessed for science or medicine, to reproductive cloning which many view as 
an extremely slippery slope to pursue (8). This slippery slope is based on a 
number of concerns, including possible threats to human diversity, health risks 
for clones, the problematic establishment of moral status and rights, the effect 
clones may have on natural human dignity and identity, as well as numerous 
other social implications which due to the scope of this study we are unable to 
further explore.  
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Figure 6: How Therapeutic Cloning Could Work (5) 
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With the increased awareness of the need to find alternative sources of human 
embryonic stem cells, researchers are not far from perfecting this process. 
Nonetheless, there exists one major ethical objection to the perusal of this 
method, namely the means needed to acquire a sufficient amount of eggs needed 
to achieve any kind of impact. 
The Commercialisation of Egg Donation 
Due to the inefficiency of this technique, therapeutic cloning requires a vast 
supply of human eggs until the technique can be perfected. As this is yet to be 
the case, the main issue of SCNT is that relying on voluntary egg donations alone 
would not produce a sufficient amount of eggs needed for this cause. A legitimate 
concern is highlighted by J.R. Meyer (8) concerning the likely occurrence of 
unregulated and intensive hormone treatment as well as ovary stimulation which 
might expose those who choose to go through with the procedure to serious 
health risks and exploitation (8, 10).  De Melo-Martin explores the topic of IVF 
practises, paying special attention to the risks women would be taking on if an 
associated moral obligation was placed upon them to supply medical science with 
eggs (29). 
However the health risks posed are not the only ethical issues preventing full 
endorsement of this method. Another ethical issue links in with an issue of social 
justice. A common perception is that in order to meet the demand for eggs, the 
act of supplying eggs might need to be monetarily endorsed. It is cautioned that 
such commercialisation could lead to the exploitation of emotionally and/or 
financially vulnerable women (3). 
In this case, that which should be a voluntary altruistic donation for research 
purposes could potentially be transformed into a coercive situation resulting in 
those who are economically disadvantaged in society being exploited for the 
potential benefit of the more economically stable populace, i.e. the stem cells of 
the less disadvantaged are used by those who can afford such health 
technologies and not by the donors themselves.  
Education and level of literacy play an important role in determining whether a 
person is able to get a job. Being poor, uneducated and illiterate can, and does, 
force many women to sell their bodies (30).  
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With the advent of payment for female eggs, this commercialisation may cheapen 
the innate dignity of the bodies of these women who know no better than to 
partake in a degrading and inhumane exercise (8).  
A feminist interpretation of this ethical issue is that the choice to undergo hormone 
treatment resulting in the production of eggs as well as payment in lieu of these 
eggs, is solely the choice of the woman herself. It is her personal autonomous 
decision to do with her body as she sees fit. It is argued that by consenting to 
such an agreement, a woman is exercising her personal autonomy and thus her 
bodily integrity must be respected by allowing her to make this decision.  In the 
opinion of the author, this is quite a Western interpretation of autonomy whereby 
the emphasis is placed on the woman's ability to decide for herself. In some 
Eastern cultures, the decision to consent to such acts is not solely up to the 
individual, but takes into account the familial involvement as a whole. (ref, me 
essay East v West).  
It has been argued that by paying women to donate their eggs, commercialisation 
of the human body occurs by placing a monetary value on specific tissues and 
body parts (8). Ethically speaking this is in direct conflict with the Kantian maxim 
which emphasises the immorality of treating another human being as a means to 
an end, rather than a means in and of herself.  
Conversely, it has also been argued that it is only fair that women should be paid 
for their bodily donations; it is expanded that as it is normal practice to 
compensate those who take part in research trials, be it through financial gain or 
benefits in kind (3), then relatively speaking the same should be the case for 
women who undertake the risks associated with egg donations. An essential 
question that needs to be asked is whether it is possible to find a 'fair price' which 
one can pay a women to adequately compensate her for the risks, time and 
productive of same?  
As Jennifer Parks notes, with reference to the surrogacy industry, "reproductive 
tourism may lead to a 'race to the bottom' in which the countries with the most 
permissive reproductive laws fight one another by cutting prices in order to 
compete for the business of reproductive tourists" (30).  
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The same argument could be levelled against commercialising egg donation; 
although the time frame is a lot less in length than gestational surrogacy, the risks 
are just as high and if anything more frequent. 
Creating in Order to Destroy 
In an attempt to circumvent the ethical problems associated with SCNT, a new 
technique was proposed by William Hurlbut called Altered Nuclear Transfer. In 
this technique, a gene within the somatic cell’s nucleus, which is necessary for 
implantation to occur, is ‘deactivated’ or genetically modified so that it is ‘turned 
off’ (3). Once this has occurred, the nucleus is transferred into the enucleated 
egg cell. Due to the genetic manipulation the new cell is now referred to as a 
Biological Artefact as it has been brought into existence with a genetic structure 
which is insufficient to generate a human embryo (10). The definition of 'Biological 
Artefact' should cause one to pause; the author claims that within the article 
referenced, the term was not fully explored and so the characteristics of what 
makes the modified embryonic cell a biological artefact instead of an embryo 
were not clarified. Such clarification is of the utmost importance both ethically and 
legally, especially when in relation to embryonic research and procurement.  
In the unlikely event that this 'artefact', which resembles an embryo cell, is 
implanted into a womb the new embryonic-like-cell will not be able to implant and 
so will never be able to develop. Thus, one could argue that the ethical 
controversy surrounding the right to life debate has been resolved; that because 
this embryo-like cell lacks even the capacity to develop, it cannot be ascribed the 
personhood of which embryonic development plays such an important role. 
Opponents of creating embryos solely for research purposes are in stark 
disagreement with this ‘ethical resolution’. It has been queried whether the claim 
Hurlbut proposes - that no embryo creation or destruction takes place - has an 
actual basis. It is not the production of a non-human entity which causes this 
worry but the possibility that in this instance the deliberate creation of a doomed 
or disabled embryo occurs.  
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As explored above, it is the intent which the researchers employ with makes the 
act immoral. Thus, the intentional maiming of what could be a viable embryo is 
viewed as morally worse than if researchers were to use a surplus embryo.  
Scientifically speaking, this alternative method has sparked warnings from the 
medical community as currently it is unknown if the genetic modification effects 
the productivity and proliferation capacity of the resulting stem cell lines.  
Which Cell has the Right to Life?  
A central criticism aimed at Single Cell Blastomere Extraction is based on the 
premise that, through extraction of a base cell of an embryo, i.e. one of the first 
divisions, the extracted cell might share the Totipotency of the initial zygote. Thus, 
the whole controversy of right to life could be reset but this time in defending the 
rights of the newly produced Totipotent cell (10). If the new embryonic cell has 
the capacity to differentiate into all other types of cells which make up a human 
organism, indeed if it can develop into an organism, the rights of this new kind of 
asexually produced being will need to be addressed as well. It can be said 
therefore that this alternative method does not in fact bypass the ethical concerns 
raised by the normative method of obtaining human embryonic stem cells.  
5.4 Unethically Obtained Research 
 
Another issue relating to consent is one which advocates that if an embryo is to 
be considered as a fully-fledged human person then it may be argued that no 
consent is given to the researchers by the embryo to carry out the invasive, life 
threatening procedure. This is one of the stronger arguments which should cause 
many advocates of human embryonic stem cell research to pause.  
With the atrocious treatment of the victims of the Holocaust experiments still fresh 
in the world’s medical history, as well as the crowning achievement of ethical 
error through the Tuskegee Syphilis experiments, the weight of being equated, 
even partially, to a Nazi Doctor appears to be a turning point for many. Can it be 
argued that using research results which were obtained through immoral, 
sometimes even repugnantly evil, experimentation is unethical?  
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A vast amount of controversial debate stemmed when the decision was made to 
use the results of the barbaric experiments performed by the Nazi Doctors. 
Similarly, there are some who view utilising the results of human embryonic stem 
cell research to be unethical and based upon a fallacy which endorses the view 
that as an embryo does not have the capacity or even the capability to consent, 
the consent is not required or invalid.  
The author suggests that if this view were to be applied to incapacitated adults, 
i.e. those who lack the capacity, rationality, consciousness, etc. which according 
to those who subscribe to the cognitive definition of personhood shows personal 
autonomy is present, the result would be moral uproar. Does a deciding 
difference exist between these two groups? A key component of the argument to 
protect these groups is their vulnerability. Many understand and advocate that 
even though these individuals may not have the ability to defend themselves, 
safeguards need be put in place to ensure that they are not exploited by others 
who view them merely as bodies ready to be harvested for scientific gain (31).  
The point could be argued that this was the rationale behind the production of the 
many versions of human research guidelines as well as human rights doctrines 
which are enshrined in law all around the world today (31).  
Hence, the argument can and has been made that although embryos appear less 
than human, they are in fact deserving of the same protections which are put in 
place for the living, vulnerable groups of society. These protections, guidelines, 
as well as the definitions which uphold them will be explored with more scrutiny 
in the following chapters.  
________________________________________________________ 
The Ethical issues outlined above have helped to illuminate the difficulty and 
elusiveness which characterises the human embryonic stem cell debate. It is only 
through comparison to the above ethical issues where an honest appraisal of 
whether induced pluripotent stem cell research is capable of resolving same.  
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6. Does Induced Pluripotent Stem Cell Research Resolve the Ethical Issues 
of Human Embryonic Stem Cell Research? 
 
This chapter aims to clarify if the introduction of an alternative method of obtaining 
stem cells, namely induced pluripotency, alleviates the ethical issues raised 
through human embryonic stem cells research.  
6.1 The Beginning of Life 
 
Where moral activists seek to protect the vulnerable life of an unborn foetus, 
medical researchers appear to have found a way to circumvent the moral 
objections of stem cell research by inducing pluripotency in somatic cells. Rather 
than endangering, or destroying the life of an embryo, be it donated or created, 
this method of obtaining embryonic-like stem cells appears to resolve many of 
the issues which opponents of human embryonic stem cell research opine.  
Religious Influences 
In relation to the religious influences which in more instances than not heavily 
impact the permissibility of human embryonic stem cell research, the induced 
pluripotent stem cell method appears to help alleviate the moral problems 
associated with such perspectives. This is primarily due to the fact that method 
of obtaining iPS cells technically does not necessitate the destruction of an 
embryo. Thus, whether or not religious influence impacts individual perceptions 
of this alternative method seem superfluous as the main qualm religious believers 
hold against human embryonic stem cell research is the supposed immoral 
destruction of an embryo. 
That said, a  technicality arises when a kind of reductio (14) argument is 
advanced, whereby due to the pluripotency of said iPS cells it may be proposed 
that any and all somatic cells which are reprogrammed to become embryonic-like 
stem cells are in fact embryonic cells (14). In turn it appears as if pursuing the 
induced pluripotent stem cell technique is redundant and does not in fact resolve 
the moral dilemma of whether an embryo, or embryo-like cell, deserves 
protection.  
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This line of reasoning has been described by many as fallacious, to say the least; 
it is imperative that the difference between embryonic cells and embryonic-like-
cells is emphasised otherwise a danger exists whereby no alternative method of 
obtaining embryonic-like-stem-cells will be deemed ethical.  
One may question here if a difference exists at all? If the latter is as potent in its 
ability to differentiate as well as proliferate, does a difference exist? Soren Holm 
had already affirmed a difference between embryonic cells and embryonic stem 
cells, emphasising that embryonic stem cells are those which are derived from 
embryonic cells and which are not embryonic cells in their own right (14). By 
extension, it can be argued that somatic cells which are reprogrammed to 
become induced pluripotent cells which are not identical to embryonic stem cells 
(8) and are far enough removed from an embryonic entity to deem any argument 
or link to embryonic destruction weak and nonsensical. 
Definitions and Interpretations 
With the introduction of induced pluripotency the ambiguous terms employed 
within the beginning of life aspect of the stem cell debate possess less of an 
impact on the morality of utilising stem cell technology. Use of elusive terms such 
as 'personhood' and 'person' appear somewhat out of context when applied to 
somatic cells which have been reprogrammed through the use of biological 
factors to become pluripotent. One of the major issues which may come to pass 
in this respect would be the legal definition of the reprogrammed cells, i.e. if the 
cells are capable of being reprogrammed to sex cells, are they to be afforded the 
same rights and protections as embryos or sex cells, or are they to be treated in 
a similar fashion to organs which, although they potentially may save a life, do 
not constitute as a life by themselves?   
As explored above, more research is needed to elaborate on the distinguishing 
differences between what constitutes as a 'Biological Artefact' in opposition to a 
living body which requires legal and moral protection. This aspect of 
distinguishing between basic cells and living cells receives further scrutiny in 
chapter seven, within the legal parameters of the debate.  
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Potentiality Argument  
The issue of potentiality is not unique to induced pluripotent stem cells, indeed it 
has plagued the debate of human embryonic stem cell research for decades. As 
the issue of potentiality in the human embryonic stem cell argument is based 
upon the premise that a human person is being destroyed, the issue of potentiality 
in this respect within induced pluripotent stem cell research is less problematic. 
Indeed, proponents of induced pluripotent stem cell technology argue that 
although the potential exists for somatic cells to be reprogrammed to become sex 
cells, or even an embryonic cell, there is no reason to believe that every case of 
induced pluripotency will result in the creation of such cells. Certainly, the entire 
point of exploring a different method of obtaining stem cells through induced 
pluripotency was to circumvent the ethical issues which stem from the existence 
of an embryonic entity or stem cells created from this entity. Thus the existence 
of the potentiality argument, especially in relation to utilising somatic cells within 
induced pluripotent stem cell research, does not provide a stable foundation to 
limit research into this valuable area of medical insight.   
Through this analysis of the impact of induced pluripotent stem cell research it 
appears as if it undeniably resolves many of the ethical issues in relation to the 
beginning of life. Nonetheless, other ethical issues in relation to alternative 
methods of obtaining human embryonic stem cells exist, especially in relation to 
the social implications these create, and these need to be balanced against the 
discovery of induced pluripotent stem cell technology.  
6.2 Alternative Sources of Human Embryonic Stem Cells 
 
With the advent of induced pluripotent stem cells the search for other alternative 
sources of embryonic stem cells has slowed somewhat. This is mainly due to the 
diverse and complicated social problems which such alternative sources may 
create, and which induced pluripotent stem cells appear to sidestep.  
IVF - In Vitro Surplus / Supernumery Embryos 
The new alternative use of inducing pluripotency helps to settle the social and 
ethical issues caused by the practise of producing supernumery embryos.  
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Where the possibility that couples undergoing IVF treatment were potentially 
being manipulated and harnessed for their embryos, the introduction of a viable, 
possibly infinite, source of pluripotent stem cells via induced pluripotency, 
redirects the focus of scientific research away from the need to harvest unwanted 
or spare embryos and forces it to focus its energy instead on the less 
controversial and more economically viable induced pluripotent stem cells (30). 
The sole problem with this claim however, would be that the method of induced 
pluripotency has yet to be perfected and thus the use of supernumery embryos 
might continue until this occurs.  
Somatic Cell Nucleus Transfer - SCNT 
One of the main controversial ethical and social issues in relation to SCNT is the 
necessity for a vast supply of eggs (ova) in order for any significant impact to take 
place. Primarily harvested from IVF centres, where female counterparts produced 
more than was needed for a successful implantation, the SCNT procedure has 
been documented as being extremely inefficient, with a 7% success rate (8). It is 
due to this staggeringly low success rate that an innumerable supply of oocytes 
is needed. However, the altruistic donation of human oocytes appears to fail to 
reach the quota which SCNT requires in order to provide some form of fruitful 
outcome. Thus, the possibility of a monetary incentive in order to meet demand 
may be utilised in various countries, for example India or Mexico where 
commercialisation of the human body has already begun (30).It has been 
cautioned that such commercialisation could lead to the exploitation of 
emotionally and/or financially vulnerable women.  
With the establishment of a safe and more efficient method of obtaining 
pluripotent stem cells, which are similar to that of embryonic stem cells, it appears 
as if such monetary enticement of emotionally and/or financially vulnerable 
women is not necessary.  As induced pluripotency appears to only require 
somatic cells, or cells which are extremely easy to obtain (e.g. hair or skin cells), 
not only does it bypass the above issue of commercialisation and the possible 
dehumanisation linked with such monetary stimuli, it in fact appears more 
financially viable than that of SCNT as well (8).  
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Due to its simplicity of production, the redundancy of commercialisation as well 
as its higher efficiency rate, it appears as if induced pluripotent stem cell research 
is better suited to large scale implementation than that of SCNT and so resolves 
its ethical and social issues (8).  
Altered Nuclear Transfer - ANT 
In an attempt to circumvent the ethical problems associated with SCNT, a new 
technique was proposed by William Hurlbut called Altered Nuclear Transfer. In 
this technique, a gene within the somatic cell’s nucleus, which is necessary for 
implantation to occur, is ‘deactivated’ or genetically modified so that it is ‘turned 
off’ (3). The central ethical issue aimed at this method is that rather than solving 
the ethical dilemmas posed by employing SCNT, ANT actually appears to create 
an even more problematic ethical problem; namely the deliberate creation of a 
doomed or debilitated embryo (10). As explored previously in many cases it is the 
intent behind an act which deems it ethical or not, and in the case of ANT it has 
been found that the very idea of manipulating a potential embryo by inserting 
something destructive into the genome, even for a good cause, is morally and 
aesthetically offensive (10). The central ethical fear in relation to this method 
would be that once medical research starts down the road of deliberately 
engineering artificial entities with some human properties, the line between what 
is ethically acceptable and what is not will become significantly blurred (10). 
As with the above ethical issues aimed at utilising embryos, even those which 
may be described as debilitated or doomed to die, the new technique of inducing 
pluripotency seems to circumvent these dilemmas and render ANT obsolete (8).  
6.3 Ethically Obtained Research 
 
As the induced pluripotent stem cell technique simply requires a somatic cell as 
a starting point, be it from a human of any age (but generally an adult) the ethical 
qualms of obtaining consent appear less urgent than in the case of obtaining stem 
cells from an embryo.  
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However, the author notes that perhaps it is because of the ease of being able to 
obtain one's somatic cells (a human being on average sheds about 30,000 to 
40,000 skin cells per hour) that more stringent consent protocols are required. 
The issue of consent is more thoroughly explored within the legal issues chapter 
below.    
Through the above exploration of the impact of induced pluripotent stem cell 
technology in the search for alternative sources of human embryonic stem cells, 
it becomes apparent that it does, to some extent, resolve the ethical and social 
issues associated with said alternative sources of human embryonic stem cells. 
Nevertheless, if the full ethical ramifications of this area are to be explored then 
it is imperative to understand that as the induced pluripotent stem cell technique 
is only in the primary levels of development, it poses its own ethical and social 
issues which require further discussion. 
6.4 The Ethical Issues of Induced Pluripotent Stem Cell Research 
Unwanted Outcomes 
 
Even though the main contributory transcription factors needed to create induced 
pluripotent stem cells have been identified, little is known concerning any future 
repercussions of their employment. Of primary import is that expression of these 
factors within the fibroblast could possibly lead to tumour formation (3). The most 
problematic of Yamanaka's factors causing tumour genesis is the c-Myc factor, 
which has been associated with some forms of human cancer (3, 4). Within the 
study pursued by Yamanaka and his team about 20% of mice derived from iPS 
cells created using retroviruses developed tumours (8). That said, this factor may 
be removed from the process, with the outcome of an embryonic-like stem cell 
still expected albeit with a reduction in the efficiency of de-differentiation (4).  
As well as this, the delivery method of these transcription factors also plays a 
major part in the resulting stem cell formation. The immediate safety concern 
about this approach is the integration of the viral DNA, which could potentially 
result in varied differentiation potential or the possibility of other malignant 
transformations (7).  
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It has since been established that transient expression of the key transcription 
factors by adenoviral vectors can also induce induced pluripotent stem cells, 
while the trans-genes will not integrate into the house genome, thereby reducing 
unwanted and unstable outcomes. 
Where Yamanaka and Thomson employ retroviral and lentiviral systems, 
respectively, each system has its own advantages and disadvantages as follows: 
(16) 
Table 2: Methods for Reprogramming Somatic Cells to iPS cells 
Vector Type Cell Types Advantages Disadvantages 
Retroviral Fibroblasts, 
neural stem cells, 
stomach cells, 
liver cells, 
keratinocytes, 
amniotic cells, 
blood cells and 
adipose cells 
Reasonably 
efficient 
Genomic 
integration, 
incomplete 
proviral silencing 
and slow kinetics 
Lentiviral Fibroblasts and 
keratinocytes 
Reasonably 
efficient and 
transduces 
dividing and non-
dividing cells 
Genomic 
integration and 
incomplete 
proviral silencing 
Inducible 
Lentiviral 
Fibroblasts, β 
cells, 
keratinocytes, 
blood cells and 
melanocytes 
Reasonably 
efficient and 
allows controlled 
expression of 
factors 
Genomic 
integration and 
requirement for 
transactivator 
expression 
Adenoviral Fibroblasts and 
liver cells 
No genomic 
integration 
Low efficiency 
 
Problems of tumour genesis aside, the efficiency of converting somatic cells to 
iPS cells is still relatively low, meaning that while the possibilities seem endless, 
their achievement might be further away than anticipated (17).  
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In an attempt to circumvent this problem, researchers have attempted to use cells 
which are more specifically differentiated in the first place, i.e. kidney cells, to 
create iPS cells.  
It has been found in some cases that human hair cells appear to de-differentiate 
at a faster rate and possess more potency than human somatic cells (11). 
However, through their analysis it was found not only that specialist cells are 
harder to de-differentiate (12) but also that there seems to be more than just a 
barrier of reprogramming halting their progress; known as Epigenetic Memory, 
the de-differentiated cells seem to conserve some of their 'memory' of what their 
purpose was prior to de-differentiation thereby limiting the new application of the 
iPS cell (4, 32). The author recommends that further research is needed to 
overcome this barrier before the advent of clinical human trials.  
Until a more stable method of expressing the necessary transcription factors is 
developed both to halt the formation of tumours as well as to increase efficiency, 
induced pluripotency will be restricted in its scope and human application will 
remain a far off possibility.  
Justice 
A central ethical issue of induced pluripotent stem cell technology is in relation to 
the possibility of personalised stem cell lines for each individual the world over. 
As mentioned above a primary motivating factor for the development and 
research into stem cells (and by extension induced pluripotent stem cells) is the 
possibility of one day being able to produce stem cells on a mass scale but in an 
individual capacity, i.e. each person could theoretically have their own stem cell 
line in a stem cell bank, perhaps waiting in stand-by for when it is needed. While 
the theory behind such a claim is admirable, in a more grounded understanding 
of the current world climate with regards to healthcare availability and cost, such 
a feat can be described as physically unobtainable (4).  
Due to this, Yamanaka as well as Taylor et al. (4) put forward the idea of creating 
international and national banks of HLA-typed human induced pluripotent stem 
cell lines, i.e. international and national banks of induced pluripotent stem cell 
lines created specifically to replicate the antigen proteins of different groups in 
the population.  
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With the advent of such banks, it will not be necessary to create an individualised 
stem cell line per person, as "generic" stem cells will hypothetically be readily 
available to all who need it.  
As well as this, through the establishment of these banks the cost of obtaining 
stem cells may be reduced (4) as it could very well be argued that such a product 
should be funded through the healthcare operations of each state. In the opinion 
of the author, social ramifications of this may have wide ranging ramifications for 
those countries which are not currently able to provide basic healthcare never 
mind semi-personalised stem cells for each individual HLA-typed group in their 
populations.  
The method of inducing pluripotency in somatic cells appears to help resolve or 
alleviate the main controversial aspects of human embryonic stem cell research 
and application, namely the destruction of viable embryos as well as alternative 
methods of obtaining same. Nonetheless, it need be noted that induced 
pluripotent stem cell technology triggers its own ethical dilemmas, which in turn 
would seem to complicate rather than simplify the original aims of establishing a 
morally acceptable means of obtaining pluripotent stem cells. Even so, all new 
technologies carry with them ethical ramifications and as the induced pluripotent 
stem cell method is still very much in early development and modification, it can 
be assumed that such complications will be resolved themselves in the years to 
come.  
Some of these complications are directly in relation to restrictive stem cell laws 
which vary significantly from country to country.  As induced pluripotency has only 
recently established itself as a viable alternative method to human embryonic 
stem cell research in the last decade, a vast amount of current legislation 
concerned with stem cell regulation and policy fails to recognise this new method.  
Therefore it is essential that the current foundation of stem cell regulation and 
law, even if only in relation to human embryonic stem cell research, is extensively 
analysed for weaknesses or ambiguity so that prospective alternative methods of 
obtaining stem cells, including induced pluripotent stem cell research, are 
governed by regulations which are both robust and clear in nature.   
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7. Legal Issues of Human Embryonic Stem Cell Research 
 
Legal regulations and guidelines in each country around the world are influenced 
by numerous factors ranging from the dominant religious beliefs the country holds 
to whether it is a member of a congregation of states e.g. the European Union or 
the United Nations. While many countries enjoy a more liberal legal interpretation 
in relation to bioethics and human embryonic stem cell research (3), there are 
some which remain steadfast in their traditional beliefs who remain as yet 
unconvinced that the potential benefits of this medical technology outweigh the 
moral dilemmas it poses. The legal issues within this area of research are 
intimately linked to the ethical controversies highlighted in the previous chapters. 
Although efforts are made within the legal sphere to separate personal moral 
convictions from civil matters, due to the extremely recent and unfamiliar nature 
of the cases which stem cell technology and research presents, legal interpreters 
have little to no precedents on which to base any kind of guidelines or regulation. 
Hence it is understandable that judgements and legal implementations are 
unique in individual countries, to some degree. This chapter seeks to explore the 
various legal instruments from developed countries around the world in relation 
to human embryonic stem cells, the legal definitions enshrined or purposefully 
excluded within these, namely the definition of ‘person’, current guidelines on the 
patentability of human embryonic stem cells, as well as the legal parameters in 
relation to the concept of consent.  
7.1 Current Legal Guidelines and Legislation on Stem Cells 
 
Medical breakthroughs in relation to stem cell research are becoming more 
frequent due to the exponential progress made in the last decade within this field. 
Although these discoveries may be informing further research, the author notes 
that regulation is approaching a point where it is unable to keep up, or is found 
lacking. In such a field as stem cell research, where the controversial definitions 
as well as cultural influences become deciding factors, clear and concise, legally 
binding regulations have been called for (33). 
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An appraisal of the divergent legal positions of countries around the world serves 
as an attempt to elucidate this grey area of the stem cell debate, and is located 
in Appendix 2 of this thesis (7).   
This analysis of the various global stem cell laws clearly illustrates the amount of 
diverging regulations which exist amongst countries from Europe, America and 
Asia. A world map which reflects the current policies adopted by different 
countries can be found in Appendix 3 of this thesis, which may further aid the 
reader in understanding the divergence between countries on this important 
topic.  
Where some countries outright prohibit any kind of research on human embryos, 
for example Lithuania, Germany and France, other countries have authorised it 
albeit with some strict conditions which need to be fulfilled, for example the UK, 
Spain,  and Italy. These conditions depend on each country’s laws and ultimately 
are shaped by the political and social climate of each government.  
In France, for example, the use of human embryos and embryonic stem cells is 
prohibited unless the following specific conditions are met (7):  
 That the research is scientifically relevant 
 That the research is likely to allow major medical advances 
 That it has been expressly established that the research cannot be 
performed unless cells derived from embryos are used 
 That the research project respects French ethical principles for research 
on embryos and embryonic stem cell lines (7). 
Similarly in the UK, although human embryonic stem cell research is authorised 
subject to a licence from HEFA, any such research is strictly regulated and only 
permitted when the following conditions are met, such as: 
 The HFEA is completely satisfied that any proposed use of embryos is 
absolutely necessary in order to achieve the purposes of the research (7) 
 The research can only take place on embryos which have developed from 
eggs outside the body, i.e. in vitro embryos 
 This research can only take place on embryos up to 14 days old 
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The above conditions can be argued to exist although to differing degrees in most 
policies employed by other countries, the majority of which are based in Europe 
(7).  
Germany, for example, has a very restrictive regulatory framework in comparison 
to other EU countries. Under the Embryo Protection Act 1991, the derivation of 
an embryonic stem cell line is a criminal offence. The Basic Law of Germany also 
affirms that everyone has the right to life, which appears to have been interpreted 
as meaning embryos as well, although The Basic Law does not elaborate further 
on the meaning ascribed to the word "everyone". German Law, like the majority 
of EU countries, gives priority to adult stem cell research. While the 2002 Stem 
Cell Act permitted adult stem cell research, it had a strict importation of human 
embryonic stem cell lines regulation which included a cut-off date in relation to 
when said stem cell lines were established. The initial date proposed was 1st 
January 2002, but this was then pushed to 1st May 2007, as a result of pressure 
from German researchers and scientists. This cut-off date stipulated that any 
human embryonic stem cell lines which are created after 1st May 2007 are 
prohibited from being imported and used for research purposes (7).In an attempt 
to further protect and respect the life of the unborn, in 2006 Germany pushed for 
a ban on all embryonic stem cell research in the EU. However due to the 
divergence of culture, history, government, and regulation, an EU-wide blanket 
ban would not be possible, in the same way that an EU-wide authorisation of such 
research would also not be possible. Other countries, however have less rigid 
regulations and are more open to the potential such research harnesses.   
With a comprehensive regulatory framework, Spain appears to have a more 
lenient stem cell regulation, allowing stem cell research both for research 
purposes as well as therapeutic application. The Law on Biomedical Research 
(Law 14/2007) is the leading regulation on this matter. It prohibits the creation of 
human embryos (and pre-embryos) which would be used exclusively for 
experimentation.  
That said, the law allows the collection of human embryonic stem cells from pre-
embryos or embryos based on the condition that the embryos are not solely 
created for this purpose (7).  
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Having such an inclusive regulatory framework has placed Spain in a strong 
position with regards to furthering scientific knowledge and application of stem 
cells.   
In contrast, the United States appears to have had a very conservative approach 
to stem cells. The Roe v. Wade case, which legalised abortion in the US in 1973 
as well as developments occurring in England around that time prompted the 
federal government to create a regulation which banned any form of federal 
funding for research which would experiment on human embryos (34). Two 
decades later, in 1995, the US congress passed the Dickey Amendment, which 
was part of an appropriations bill. The Dickey Amendment was more specific than 
previous regulation in the area of experimentation on human embryos; it 
authoritatively prohibited the creation or destruction of human embryos for 
research purposes. This bill was passed prior to the establishment of the first 
human embryonic stem cell line. Due to this, the Dickey-Wicker Amendment did 
not detail the precise definitions of what constituted a human embryo. This 
became apparent once human embryonic stem cell lines began to be established 
in the late nineties; in 1998 James Thompson of Wisconsin University sought to 
clarify that the National Institute for Health (NIH) could in fact fund any research 
which was conducted using stem cells obtained from these lines. Thompson 
opined that stem cells obtained from these lines were not human embryos 
according to the statutory definition and thus researchers were eligible for federal 
funding as no embryo were being created or destroyed. While President Clinton 
thoroughly endorsed this interpretation, between 2001 and 2006 President 
George Bush signed an executive order which restricted any kind of federal 
funding for human embryonic stem cell research. This restriction limited funding 
by only granting it to those who utilised stem cells obtained from stem cell lines 
already established prior to August 2001. 
Due to the restriction of funding, stem cell research in the US during the early 
2000s did not flourish at the same rate as other countries which had more lenient 
funding systems, for example, the UK. However, in 2009 President Barack 
Obama signed a different executive order which reversed federal opposition to 
stem cell research (35).  
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It can be a difficult scientific and ethical balance for policies to reflect the desire 
for progress in managing disease, but at the same time attempting to maintain 
the collective moral views of a nation.  
Even if a country was able to create a harmonious balance between the ethical 
and the legal issues at play, the limits of language and its interpretations impact 
these regulations on a consistent basis. This is in particular due to the re-defining 
and development of terms as research exponentially progresses.  
7.2 Legal Definitions and the Right to Life 
 
As much as these laws serve to enlighten the stem cell debate, where no solid 
definitions are given, they can lead to confusing situations and leave loopholes 
waiting to be exploited. Arguably one of the key issues related to human 
embryonic stem cell research is the interpretation and meaning of the Right to 
Life.  
While specific objections related to human embryonic stem cell research have 
yet to surface in the legal sphere for individual lawsuits (with federal or 
government funding of such research taking much of the limelight), certain cases 
where an unborn embryo's right to life has been considered have influenced the 
possible formation of legal precedents in this complex area. These cases are in 
relation to reproductive autonomy as well abortion. Intricately linked to the 
treatment of reproductive issues and abortion laws is the question of personhood 
and the disagreement over when human life begins (36) and what defines it. 
In Ireland, for example, an important case M.R. v. T.R. (37) may have set a 
precedent for any future stem cell regulation which the country may develop. In 
this case, a husband and wife went through the process of IVF treatment; some 
of these embryos were stored for later use; the couple separated; the woman 
wanted to use some of the embryos; the man wished for them to be destroyed; 
the woman took the case to the High and then on to the Supreme Courts to appeal 
the decision. In this case, the woman employed the argument for the embryo's 
Right to Life and demanded that this be respected, and that she be authorised to 
use the embryos.  
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Known as the 'Frozen Embryos' case, it highlights how an important Article within 
the Irish Constitution, as amended by a referendum in 1983, is an accurate 
example of ambiguity within Irish, as well as international, regulation with regards 
to reproductive autonomy, and by extension, human embryonic stem cell 
research.  
Article 40.3.3 provides : “The State acknowledges the right to life of the unborn 
and, with due regard to the equal right to life of the mother, guarantees in its laws 
to respect, and, as far as practicable, by its laws to defend and vindicate that 
right” (38). 
The ambiguity here arises from the lack of an accompanying definition of the 
“unborn”.  Due to this both medical researchers and legal professionals were 
unsure if the protection which had been accorded to the unborn could be 
extended to embryos currently being cryo-preserved. In 2009 the Irish Supreme 
Court agreed with the High Court's decision (of 2006) that embryos which are 
held in cryopreservation and are held outside of the womb are not protected 
under the constitution (7). Arguably this precedent could be employed (or 
exploited) by human embryonic stem cell scientists within Ireland to support their 
research which destroys the potential life of an IVF Supernumery embryo.   
A different case which also highlights the need for clearer legal parameters in 
relation to the beginning of life, personhood and the Right to Life, is the Roe v. 
Wade case which took place in the United States in 1973. While this case deals 
with abortion, similar to the above, indirect conclusions can be derived and 
applied to modern human embryonic stem cell research. In this case, the issue 
of when human life truly begins, i.e. when an embryo acquires personhood status, 
came to the fore. While establishing the right to an abortion in the first trimester, 
the decision of the Supreme Court states the right to intervene in the second and 
third trimesters of pregnancy to protect the woman and the "potential" life of the 
unborn child.  Thus the courts were demanded to pinpoint the exact time when 
this 'potential' life of an unborn child begins. The court deflected this appeal by 
employing the term 'viability'. The court outlined that the viability of an 
embryo determined the permissibility of abortions performed for reasons other 
than the protection of the woman's health. 
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It went on to define viability as "the point at which a foetus is potentially able to 
live outside the mother's womb, albeit with artificial aid" (39). 
This interpretation of the viability of embryos being something directly linked to 
its personhood, humanity and protection, led the public to fear the possible 
exploitation of embryos which were younger than the age of viability and which 
could be aborted, used or destroyed in an unregulated and unethical way by 
medical science.  
What this definition lacked was clarity surrounding its terms - particularly with 
regards to embryos which are developed in vitro for research purposes, through 
the use of artificial aid, which may never have the opportunity to reach the stage 
of being characterised as a 'foetus'.  
The effect these two cases have had is to force the general public to confront 
those legal regulators, who have the ability to stimulate change, do to so in order 
to either protect the innocent interpretation of early embryonic life or to justify why 
this protection is not afforded. It must be noted that these court decisions were 
not meant to be used as a basis for stem cell research law and regulation, but 
the structure of law as it is in many common law countries relies on precedent 
and once a precedent has been set, it's difficult to challenge. This is why further 
clarity is needed by courts dealing with such sensitive issues as personhood, the 
right to life, IVF and abortion.  
7.3 Legal Parameters of Consent and Confidentiality  
 
The issue of consent, although steeped in ethical and philosophical reflections, 
finds its true recognition through the voice of the law. Deriving much from the 
Nuremberg Code as well as from the Belmont Principles, current laws relating to 
the donation of tissue heavily emphasise the need for explicit, informed consent 
to be given prior to any kind of medical research, operation, or process. Positions 
regarding research on human embryos may be even more nuanced and complex 
than normal medical research (40) due to the sensitive nature of the subject. 
(Some have even argued that the act of donating an embryo to research accords 
it greater respect than the act discarding it (40).  
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The concept of consent is intimately linked with that of personal autonomy. 
Indeed, giving one's consent to an act, or donation, is often described as an 
expression of personal autonomy. It may be argued, as above, that in the case 
of the foetus, such expression of consent is not possible. While some argue that 
this supports the idea that a foetus is not in fact a person, others look to the 
Belmont report which stipulates that "respect for the immature and the 
incapacitated my require protecting them as they mature or while they are 
incapacitated" (31). Thus it could be argued that the embryo does not give its 
consent, and so the destruction of its life through the process of deriving human 
embryonic stem cells is wrong.  
This is where the idea of substitute consent forms; explored within his article A 
Regulatory Argument Against human embryonic stem cell research, Stephen 
Napier outlines the concept of substitute consent. He suggests that substitute 
consent occurs when a guardian(s) or state step in to decide what may be best 
for the embryo. He employs the use of a risk-benefit ratio.  
The risk-benefit ratio is a ratio Napier proposes to compare the weight of risks 
versus the weight of possible benefits of an act. Generally an act is deemed 
permissible if the benefits outweigh the risks. The ratio finds expression more so 
in circumstances where an individual or group are unable to provide informed 
consent, most likely due to their vulnerable nature. The risk-benefit ratio takes 
into account the risks associated with the research and through a process of 
extension and application to the test subject's position, evaluates whether 
consent, and the degree of it, is required. For example, even if autonomous 
subjects give their consent, a risky research project is not ethically justifiable.  
Napter applies the risk-benefit ratio to the idea of substitute consent and 
highlights a major problem, namely that rather than taking into account solely the 
risk-benefit ratio of the embryo, the one making the decision may have been 
unduly influence or coerced into a specified choice which can alter what would 
be the 'right' decision on behalf of the embryo (31). 
An example of this would be if the substitute consent is given by the genetic 
parents of the embryo in lieu of payment for their embryo.  
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Here, the risk-benefit ratio is subjective to the donating parents, and little thought 
is given to that of the vulnerable embryo i.e. rather than weighing the potential 
risks and benefits which will directly impact the embryo, the parents solely focus 
on their own potential benefit and proceed to put the life of the embryo at risk.  
If the idea is accepted that an embryo should be considered as possessing some 
form of innate personhood, due to its lack of physical capabilities it can be argued 
that it should be considered as a vulnerable person which requires substitute 
consent for all procedures.  
Therefore if it is exposed to greater risk than benefit through the process of 
human embryonic stem cell research, then it is imperative that unbiased 
regulations are put in place to protect vulnerable groups such as these. The more 
vulnerable a subject is, the greater the need to protect that subject (31).  
While employment of this ratio may highlight concerns which are overlooked by 
medical researchers, in the opinion of the author Napier did not do the ratio justice 
in his explanation and rather than emphasise the need to focus on those 
vulnerable in society, he confused his readership with the introduction of his ratio. 
An alternative route which he could have employed could have been through 
recourse to John Rawls' A Theory of Justice, where the issue of potential 
vulnerability is a significant factor (41).  
The Belmont Principles are one attempt to outline and implement regulations 
which seek to protect those who are vulnerable within society. There are three 
main principles which are central to the Belmont Report;  
 Respect for persons: This regulation comprises of detailed stipulations for 
groups whom can exercise personal autonomy and choice, as well as 
those who are unable to exercise their autonomy.  
 Beneficence: The ethic of beneficence embodies two essential 
characteristics of biomedical ethics, specifically, do no harm and 
maximise benefits. 
 Principle of Justice: Stipulates that researchers must avoid selecting their 
test subjects on the basis on "their easy availability, their compromised 
position or their manipulability" (31). 
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Consent in relation to every day matters, such as shaking someone's hand or 
allowing someone to give a massage, is on a much less intense scale than the 
consent required for that of new and untested medical research, i.e. The kind of 
consent necessary for a risky medical procedure which has little or no benefit 
may carry greater weight due to the greater risks which the patients may be 
exposed to, as highlighted through the risk-benefit ratio.  
There exists a wide degree of consensus about the main substantive elements 
of a regulatory approach. Briefly summarised the main elements of regulating 
human embryonic stem cell research and consent are as follows (18): 
 Autonomy of the gamete and embryo donor needs to be respected at all 
times; 
 This respect can be epitomised through the action of giving informed 
consent; 
 This consent is only valid if it is free of untoward influence or inducement; 
 Such consent is only fully informed once the donor understands:  
o The risks of the procedure to donate 
o What will happen to the embryo in derivation of ESCs 
o Alternative uses of embryos 
o That the donated material may be stored for years 
o That no restriction of who might benefit from the donation exists 
o That the research results may have commercial value, in which the 
donor will not share 
o That there will be no direct medical benefit to the donor 
o That information relating to the donor's identity might be retained 
o That this donated material may be employed in future, as yet 
unrealised, research and may be made available to use in medical 
procedures 
As the last point highlights, the issue of informed consent within the debate of 
human embryonic stem cell research is not restricted to the diverse scientific 
understandings and developments of the current day and age. Philosophical 
considerations which are linked with defining legal parameters of consent have 
acknowledged the need to question exactly what and to what extent patients 
are consenting (to) when they donate their embryos or sex cells.  
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For this reason the HFEA's Code of Practice for IVF clinics highlights to those 
who are considering embryo donation the possibility that any stem cell lines which 
are created may continue indefinitely and may be used in different research 
projects (42). This is an important element for governments to consider when 
regulating stem cell research. It can be argued that in the case where the far 
reaching possibilities of their donation are not outlined, the consent which patients 
give to the research is not in fact fully informed.  
Although it may be impossible to accurately represent future research aims, 
theoretically donors could consent to general areas of research which they feel 
comfortable that their donations are being used for (40).  
An interesting case of note in regard to consent and the use of donated material 
is that of Henrietta Lacks. Henrietta was the unwitting source of cells which were 
cultured by George Otto Gey to create the first immortal cell line for medical 
research. These cells were derived from the cancer cells of Henrietta's tumour. 
Gey named the sample HeLa. Due to the immortal nature, i.e. the ability to 
continually multiply without loss of potency, Henrietta lacks' cells were used 
internationally for numerous experiments.  
Although the far reaching effects of this research stirred something of an 
exponential growth in medical and scientific research, neither Henrietta nor her 
family gave consent for her cells to be employed in such a way. It can be argued 
that at the time when this case occurred (1950s), consent was not recognised as 
being as important as it is today. Such a case causes many to question the 
morality of using research which was achieved through unethical means;  as has 
been mirrored through the controversial use of the medical findings of the Nazi 
Doctors obtained during WWII.  
In dealing with such sensitive material as human embryonic stem cells, the author 
affirms that it is important for researchers to emphasise the possible future need 
of identifying the donor, when consent is being sought from said donor. As 
explored in the Henrietta Lacks case, stem cell lines may have numerous 
applications which we have yet to discover and may equate to the theoretical 
tracing of a donor (43).  
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Such issues of confidentiality carry a heavy weight on whether or not a person 
may wish to donate. Where some may affirm that the anonymity of the donors 
needs to be protected, lest a drop in already low donations occurs, others argue 
that in order for researchers to adequately prove that consent was obtained some 
kind of code which links a donation to a donor will need to be put in place (40).  
Issues of consent aside, if certain stem cell lines are to be employed to treat 
patients in clinical trials, or through future therapeutic measures, identification of 
the donor will be needed to document appropriate screening for infectious and 
genetic diseases (40).  
While this may impact the growing need for embryo and gamete donors, it may 
be imperative for researchers to employ only those donors who agree to be re-
contacted in the future should more information or tests be necessary (40). 
What has become apparent through the above appraisal is that the essential 
aspects of consent which effect human embryonic stem cell research are the 
voluntary nature of the donations, the full understanding of the consequences of 
the donations, as well as the parameters or boundaries as to what said donations 
are to be employed. Alongside this, the issue of confidentiality and exactly what 
it pertains to needs to be examined under closer scrutiny and applied to new 
medical breakthroughs, whereby remaining anonymous may not be possible due 
to the genetic link between the donor and the donated material.  
7.4 Patenting Stem Cells 
 
Patenting is a process whereby the intellectual property rights of an invention (as 
opposed to a discovery) are owned by a particular entity, be it a person, group or 
company.  Thus only those who have invested in or who have obtained a patent 
may use or distribute their invention - usually at a high price. Patents in Europe 
currently last for twenty years (44), with the aim of allowing a kind of monopoly in 
the area of the patented invention, so that the inventor and/or investors may 
recoup the financial expenses devoted to the culmination of the invention.  
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These intellectual property rights are bestowed upon the inventor with the 
prerequisite that the inventor will publish the details of the invention for anyone in 
the world to access (44).  
The debate concerning whether or not it is appropriate to patent life forms or 
biological material has received extensive critique and exploration for the past 
decade, especially in North America and Europe (3). While the patenting of adult 
stem cells has been accepted throughout most of Europe, albeit established 
through the necessity of informed consent, a disparity in opinion occurs when the 
debate focus shifts to the allowance of patents for embryonic stem cells, as well 
as the embryos they have been derived from.  
The most notable guidelines in relation to this European debate are those stated 
in the European Patent Convention (45) whereby Article 53(a) notes that 
"inventions the publication or exploitation of which would be contrary to 'ordre 
public' or morality" (45) are those which are excluded from being patentable (3). 
A common critique of this exclusion was that the terms 'ordre public' and 'morality' 
received no further elucidation in the Convention and so European states seeking 
clarification were left to their own interpretations (46). This continued up until the 
1998 EU Directive (directive 99/44/EC) on the legal protection of biological 
inventions (47) was introduced (3) in an attempt to harmonize the field of 
biotechnology patenting within Europe (48).This Directive declared under Article 
6 that patents are not to be granted "in respect of human embryos for industrial 
or commercial purposes" (47) as this was contrary to morality (3). Through its 
incorporation into the European Patent Convention as Rule 23(d-e) the Directive 
appeared to allow the patenting of isolated elements of the human body, but only 
if these elements establish more than a discovery, i.e. an invention (3). This 
aspect of isolated elements of the human body was outlined within Article 5 of 
the Directive (48). 
At this juncture the debate of the living cells interpretation of stem cells versus 
the isolated biological function interpretation of stem cells reaches its apex. 
Where the former upholds the belief that human embryonic stem cells are living 
cells and thus deserve full respect as living beings, the latter aims to interpret the 
cells as mere biological material, comparing these stem cells to organs or limbs 
i.e. lifeless but not without biological function and merit.  
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The differing meanings proposed by each group influence the patentability of 
human embryonic stem cells within each country around the world. This can be 
seen through the above incorporation of the EU Directive (directive 99/44/EC) 
into the European Patenting Convention, which consolidated ethics as a factor in 
European patenting decisions (3, 49). Where embryos as well as embryonic stem 
cells are perceived as representing human life in its most primary form, the 
granting of patents can be understood as devaluing, infringing or violating human 
dignity (3, 50).  
However, it has been argued that the ambiguous phrasing of Article 5 in the 
Directive (99/44/EC) was employed in order to enable the granting of certain 
patents which theoretically did not clash with the Directive directly and would thus 
encourage research in the field of biotechnology (48). One of the ways this was 
done was through Article 5.1 and 5.2; namely, that (5.1) the human body, or parts 
thereof (for example genes occurring naturally in the human body) cannot be 
patented, but that (5.2) parts from the human body which have been isolated from 
their natural location in the body or which have been produced through synthetic 
means can be patented (46). This creative word play did not subdue the criticism 
aimed at the European Convention. In fact it caused other important issues which 
are linked to the allowance of patenting human biological material to be pushed 
into the legal and ethical limelight.  
One such issue which has informed the non-permissibility of the act of patenting 
human embryos or their stem cells is in relation to the commodification and 
instrumentalisation arguments. Both the Danish and French National Ethics 
Councils have emphasised that premised on the principle of non-
commercialisation of the human body, stem cells which have not been 
significantly modified should not be patentable (3). The concept of human dignity 
touched upon above assumes with it the innate non-instrumentalisation and non-
commercialisation of the human body as well as its parts (3). Due to the fact that 
the possibility of patenting has a financial incentive for it to be pursued, it is feared 
that the existence of these patents may boost research on embryos. As the 
primary source of these embryos is through Supernumery Embryos, logically 
there may develop an overabundance of surplus embryos being developed than 
would have materialized without the enticement of patenting (46). 
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Even though the European Patent Office seeks a balance between what is 
ethically moral and scientifically feasible, the European Molecular Biology 
Organisation has implored the EPO to reconsider its current standing in relation 
to the patentability of human embryonic stem cells and embryos. The reasons for 
this are related to the competitive nature of stem cell research, as well as the 
economic and health care benefits which may be accrued from such research 
(3).  
On the flip side of the same coin, by issuing patents to companies which aim to 
primarily invest in this area of research, small biological companies who cannot 
afford to pay research licenses to these patent overlords will struggle and thus 
research may be stifled (3). Such research barriers have the potential to create 
obstacles to medical development of procedures and products which may have 
significant benefit. Due to this many bioethics councils of Europe have urged the 
EPO to refrain from granting overgenerous patents with broad claims (3, 43, 46, 
50). 
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8. Does Induced Pluripotent Stem Cell Research Resolve the Legal Issues 
of Human Embryonic Stem Cell research?  
 
As induced pluripotency has only recently established itself as an alternative 
method to human embryonic stem cell research in the last decade, a vast amount 
of current legislation concerned with stem cell regulation and policy fails to fully 
elucidate and guide this new practise. As such, this leaves areas of this particular 
method open to exploitation and misuse. While current stem cell legislation has 
been highlighted in the previous section, this chapter will be dedicated to 
exploring whether the introduction of induced pluripotent stem cell technology has 
in some way or another improved the legal situation. In order to be concise as 
well as clear in exploring this question, the below appraisal will aim to identify 
how this new mechanism of obtaining stem cells effects the legal matters 
highlighted in the previous chapter.   
8.1 Current Legislation 
 
Due to the situation of both heightened scientific expectations and ethical 
tensions in relation to stem cell research, countries all over the world have 
developed differing policies as well as regulations. This concept of ambiguity was 
explored in the previous chapter, and while the uniting front of many of these 
policies was the declaration that no embryo should be created or destroyed 
specifically for research purposes, the uncertainty and questionable regulations 
governing stem cells seems not to have been effected as drastically as that of 
the ethical issues raised by human embryonic stem cell research.  This is highly 
likely to change within the coming years as induced pluripotent methods develop 
and a decrease in the demand for stem cells derived from human embryos 
occurs. However, many hold that even with the advent of such a promising 
technology, induced pluripotent stem cell research will still require human 
embryonic stem cells in order to control and cross reference any achievements 
and to regulate the safety of these cells. 
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8.2 Legal Definitions and Interpretations 
 
The predominant focus of this avenue of the stem cell debate is in relation to the 
definitions and interpretations attached to the terms surrounding early human life, 
namely ‘embryo’, ‘baby’, ‘right to life’, and ‘unborn’.  
As the method of inducing pluripotency within somatic cells does not utilise the 
life of an unborn embryo, be it created, donated or discard, one would surmise 
that this avenue of legal ambiguity has finally been resolved. Unfortunately, this 
does not seem to be the case. In September 2013, a team based in Spain 
published a puzzling article in Nature (51),where they reported being able to 
cultivate iPS cells in vivo by employing the same techniques as applied to 
cultivating iPS cells in vitro. The main question here would be is there really that 
much of a difference between the products of this comparison? Startlingly, yes 
there is! The essential conclusion drawn by this team was that the induced 
pluripotent cells which were cultivated in vivo appeared extremely similar to 
embryonic stem cells, as well as being distinctly different to induced pluripotent 
stem cells produced in vitro (16).  
This brings a new technical problem to the cutting edge of the stem cell debate. 
Where stem cells were developed in vivo it was found that they presented with a 
remarkable ability to produce embryonic-like structures (16). While this has been 
the epitome of what in vitro iPS cells were believed to be able to do, the difference 
in capability is striking. Where iPS cells produced in vitro are able to differentiate 
into any of the three germ layers, those cultivated in vivo appear to share the true 
capacity and potential of totipotent stem cells (16) i.e. being one step closer to 
the ‘Golden Standard’ ascribed to totipotent stem cells. Hence a conceptual 
problem exists; namely, the differentiation between Totipotent and Pluripotent 
induced stem cells. As this new discovery develops, will it still make sense to talk 
about pluripotent stem cells lines if in fact these lines are capable of totipotent 
application?  
While this problem of definitions does not apply immediately to current stem cell 
research, the author suggests that it is a possibility that if no proper legal 
demarcation and definition takes place, issues such as patentability as well as 
quality assurance, perhaps even safety concerns, will be prone to legal and 
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commercial exploitation. Indeed, the need to redefine legal and ethical 
boundaries seems to be transforming into a constant requirement of the modern 
medical world (16).  
8.3 Consent and Confidentiality 
 
One of the most significant issues associated with induced pluripotent stem cell 
procurement and research is that of informed consent and the associated privacy 
of cell donors (52). Similar to the issue of patient confidentiality explored in 
relation to human embryonic stem cell procurement (or alternative methods of 
procurement), the resulting iPS cell lines which are derived and developed from 
an individual will possess that individual’s DNA ‘fingerprint’ (52). A donor’s sample 
could theoretically possess an immeasurable amount of personal information, not 
only in relation to the specific individual but also in relation to his/her immediate 
family and friends (52). Any breach of confidentiality could violate the individual’s 
privacy and could result in economic or social risks (52). In the United States, the 
Genetic Information Non-discrimination Act 2008 was established as a legislative 
response to these concerns. However, the extent to which legislation such as this 
will be able to control genetic discrimination has yet to be proven. 
Social and ethical considerations which are linked with defining legal parameters 
of consent have acknowledged the need to question exactly what and to what 
extent patients are consenting (to) when they decide to either donate somatic 
cells to induced pluripotent stem cell research or, assuming it will be possible at 
some point in the future, when they choose to set up a personal or familial stem 
cell line.  
As iPS cell lines become more common place in the personal medical sphere, 
perhaps the consent which is obtained from donors/patients could include a 
paragraph similar to that found in the HFEA's Code of Practice for IVF clinics. 
This Code highlights to those who are considering embryo donation (or in this 
case cell donation) the possibility that any stem cell lines which are created may 
continue indefinitely and may be used in different research projects (42).  
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This is an important element for governments to consider when regulating stem 
cell research as it can be argued that in the case where the far reaching 
possibilities of their donation are not outlined, the consent which patients supply 
to the research is not in fact fully informed. Although it may be impossible to 
accurately represent future research aims, theoretically donors could consent to 
general areas of research which they feel comfortable that their donations are 
being used for (40, 52).  
Even if an adequate form of consent has been obtained and the process of 
forming a stem cell line has begun, a major aspect of personal privacy becomes 
apparent in the instance where an individual attempts to withdraw his/her 
consent. While traditional research standards require that an individual is able to 
withdraw his/her consent from research at any point, within human embryonic 
stem cell research (and by extension induced pluripotent stem cell research) 
exceptions to this rule appear to be the norm (52). One particular guide states 
that donors are only able to withdraw their consent until the creation of the stem 
cell line has taken place (52). Even if an individual decides to withdraw consent, 
in many circumstances depending on how the cell line has been used and in what 
jurisdictions it may be near to impossible for complete withdrawal of donor 
consent to occur (52).  
Such issues of confidentiality may constitute a major aspect on whether or not a 
person may wish to donate cells or establish a stem cell line. A popular 
suggestion which attempts to address these concerns would be to anonymise the 
data at the time of donation (52). However due to clinical, research and policy 
reasons the method of anonymising data may not be the ideal approach. If certain 
stem cell lines are to be employed to treat patients in clinical trials, or through 
future therapeutic measures, identification of the donor will be needed to 
document appropriate screening for infectious and genetic diseases (56). As well 
as this, it is possible that future clinical applications may necessitate obtaining 
follow up information concerning the donor’s health (52).  
What has become apparent through the above appraisal is that similarly to human 
embryonic stem cell research, the essential aspects of consent which effect the 
development of iPS cell lines are the full understanding of the consequences of 
the donations and the parameters or boundaries as to what  
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said donations are to be employed. Alongside this, the issue of confidentiality and 
exactly what it pertains to needs to be examined under closer scrutiny and applied 
to new medical breakthroughs, whereby remaining anonymous may not be 
possible due to the genetic link between the donor and the donated material.  
8.4 Induced Pluripotent Stem Cells and Patenting 
 
Within stem cell research and ethics, the principles of protecting human dignity 
and integrity of the person is inscribed within European Patent Law, especially in 
relation to patenting and the commercialisation of inventions based on biological 
material (16). Patenting of human materials, and more importantly inventions 
which have been built upon the destruction of human embryos, was prohibited by 
the Directive 98/44/EC in 1998 due to the moral outrage caused by such acts. 
However, a landmark decision made by the European Court of Justice in 2011 
which ruled on the Oliver Brustle vs Greenpeace case created a legal loophole 
for those wishing to one day patent inventions related to iPS cell research (16).  
Brustle, a leading German stem cell scientist who holds a patent on neural cells 
produced from human embryonic stem cells, argued against the decision of the 
European Court which found that the Directive 98/44/EC extended to prohibiting 
the patentability of “procedures involving human embryonic stem cells or cells 
that are grown from human embryonic stem cells”. Brustle challenged the court’s 
decision by contesting that the original Directive did not define exactly what an 
‘embryo’ is. Due to this, Brustle applied his own definition of what constitutes an 
embryo, which is that an embryo only comes into being 14 days after fertilisation. 
As he was obtaining the human embryonic stem cells from five or six day old 
‘embryos’, he did not believe he was in violation of the Directive (53).  
Brustle’s challenge failed as the Court affirmed that within the meaning of Article 
6 (2) (c) of Directive 98/44/EC “any human ovum after fertilisation or any human 
ovum not fertilised but which, through the effect of the technique used to obtain 
it, is capable of commencing the process of development” is to be regarded as a 
human embryo and so cannot be patented (16). 
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An immediate ban came into effect on patents which necessitated the destruction 
of a human embryo in order to obtain stem cells (16). This ban included patents 
of inventions which utilized stem cells created through the use of surplus IVF 
embryos, parthenogenesis, as well as SCNT (16).  
The legal loophole which was left open for those wishing to patent iPS cell 
inventions was in relation to the exclusion criteria advised by the Court. The way 
which the court formulated its ruling allowed the possibility to patent pluripotent 
stem cell lines as well as products derived from same (16). This occurred 
because the court used a strict definition of totipotency, linking it directly to human 
embryonic stem cells and thus specifically excluding this particular type of 
totipotent stem cell, i.e. an embryonic totipotent stem cell, from being patentable 
(16). This ruling was based upon the presumption that totipotent stem cells 
cannot be technologically created, i.e. through any other means other than from 
embryonic tissue (16). As stem cell research and technology has progressed, it 
appears as if researchers and scientists are getting closer to being able to 
produce totipotent stem cells without needing to destroy an embryo in the 
process. The latest findings highlighted above by the Spanish team in 2013 are 
case-in-point of this type of development (16).  
Directly related to the permissibility of patenting biological artefacts is the issue 
of patient ownership, or as Scott et al. label it, the issue of Reach-through Rights 
(52). Within the article iPS Cells: Mapping the Policy Issues, Scott et al. explore 
the nuances of property rights in relation to those who have donated biological 
tissue/artefacts to researchers who have then gone on to patent and possibly 
profit from the exploitation of said biological materials. The central question raised 
here would be if any of those profits are due to the people who originally donated 
their biological materials?  
One line of thought argues that even though the resultant iPS cell lines are 
genetically identical to the donor, the cells would have gone through a transition 
which transformed them into new and distinct products which bear little 
resemblance to their original composition (52). If we are to assume that the cells 
are so far removed from their original characterisation of ‘belonging to’ or ‘being 
part of’ a person, would this really limit the amount of control an individual would 
have in relation to the use of his/her cells?   
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Should donors have the right to receive financial benefit from commercial profits 
which result from lines derived from their donated cells? Are they able to “reach-
through” to future instances where their cells are utilized and exercise this right?  
In the case of Henrietta Lacks, the only form of redress her family received 
occurred in 2013, when the National Institute of Health (NIH) acknowledged the 
ethical issue of consent which had been at hand for over half a century (i.e. that 
Henrietta’s cells and genome were made widely accessible to the public with no 
form of consent from either her or her family). Consequently the NIH made an 
agreement with the Lacks family that only those who apply for and are granted 
permission to access Henrietta’s genetic data will be allowed to do so (54).The 
Lacks family have not, and will not, receive any financial compensation for the 
billions of dollars which have been generated upon the exploitation of Henrietta’s 
genes and cells (above). The issue of compensation however was made 
somewhat less important through the US Supreme Court’s decision of 2013 that 
naturally occurring genes could not be patented (55).  
This question of whether donors retain some kind of property right in their bodily 
tissues or genetic data after donating it for research purposes has been dealt with 
in many American courts, for example the case of Greenberg vs. Miami Children’s 
Hospital Research Institute. This case saw Reuben Matalon (the defendant) use 
tissue samples which had been obtained from children from the Miami Children’s 
Hospital and who had Canavan Disease. Matalon went on to isolate and patent 
the Canavan gene sequence and subsequently developed a genetic test to 
screen for the disease. Due to his patent, Matalon received royalties whenever 
this test was used. The plaintiffs of the case, namely the parents of the children 
as well as three non-profit organisations who had developed a confidential 
Canavan Disease Registry and Database in the case, argued that the defendant 
had not obtained the necessary informed consent needed for the research 
conducted.  This claim was ultimately dismissed from the court and the case went 
on to set the precedent for determining ownership of donating tissue samples in 
that its final ruling was that: individuals do not own their tissue samples when 
researchers use it for testing (56).  
However, the author notes a key consideration in this area is how well the 
approach of the US courts complements one of the central bioethical principles, 
namely personal autonomy? 
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If medical researchers are to respect the personal autonomy of their donors, 
should they not also recognise the autonomy-derived right of control over tissue 
and health information? In two Canadian cases, R. v. Dyment and McInerney v. 
McDonald, the Court supported the idea that any tissue and health information 
“remains in a fundamental sense one’s own, for the individual to communicate or 
retain as he or she sees fit” (52). Even though these cases were (respectively) 
primarily concerned with issues of consent and release of personal information, 
the fact that the courts emphasised the need to respect the privacy of patients’ 
personal health information communicates the importance which can be attached 
to reach-through rights.  
Bearing in mind the numerous cases (52) where the courts have both rejected 
(US) and upheld (Canada) the property rights of donors with regards to their 
donated tissue, confusion and uncertainty remain as current laws in this area vary 
significantly, both nationally internationally. As well as this, different philosophical 
approaches and cultural influences add even more complexity to the use of 
property rights in this context (52).  
A general concern of those hoping to one day secure a patent in relation to iPS 
cell lines and their derivation, is that patents which are already in existence which 
were based on human embryonic stem cell research may already encompass 
such methods (52). Due to this, future interest in researching iPS cells may 
diminish as prospective investors would not be able to recoup any of the funds 
supplied to such projects. This is a significant barrier which faces iPS cell 
research (52). As well as this, other questions remain as to the different extents 
which patents can be secured. Will every new variation of the reprogramming 
technique result in a new patent, or does this count as an expected step which 
researchers were to follow and thus “unpatentable”? The same question arises if 
a new type of cell is reprogrammed – will this result in a new patent as well? It 
needs to be recognised that “the patent landscape is important, not only for 
efficient research progress, but also for the commercialization and clinical 
translation of the technologies” (52).  
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If too many patents are supplied in the present climate of stem cell research there 
may come a time where medical patents may develop into a thicket too 
complicated and expensive to negotiate in order to efficiently exploit the 
technology which was originally intended for human benefit (52). 
In order for induced pluripotent stem cell research to remain as avid an interest 
to researchers as it currently is, the granting of overbroad patents in the present 
needs to be curbed. Furthermore, it may be necessary to acknowledge that 
current patent guidelines and regulation are not able to sufficiently match or 
control the pace of medical breakthroughs which are taking place in this advance 
field of bio-technology. Through this appraisal of the legal issues related to 
patenting induced pluripotent stem cells one can conclude that the advent of this 
technology does not adequately resolve the legal issues associated with the 
commercialisation of human tissue or cells which were primarily generated 
through the patenting of human embryonic stem cells. 
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9. Conclusion and Recommendations 
 
The initial positive and beneficial expectations of stem cell research has and will 
continue to appeal to both the medical and scientific communities. With the 
possibility of discovering cures for neurological, motor, perhaps even all, 
diseases on the horizon, researchers as well as the public are advocating for 
more thorough research into the availability and production of these miracle cells. 
That said, numerous ethical and legal issues have acted as a barrier to such 
research. These have stimulated the developing ethical guidelines and restrictive 
legal policies which have slowed  research and delivery of new and approved  
medical solutions. 
The aim of this thesis was to establish whether the ethical and legal issues 
caused by human embryonic stem cells could be alleviated or resolved by the 
more modern alternative approach of induced pluripotent stem cells.  
The appraisal of the ethical issues generated by human embryonic stem cells 
found that the introduction of induced pluripotent stem cells as an alternative 
method of obtaining stem cells would alleviate or resolve many of these issues: 
Key among these is that induced pluripotent stem cells do not utilise an embryo 
as a means of producing stem cells. Induced pluripotent stem cells usage of 
somatic skin cells as opposed to human embryonic stem cells is a significant 
factor in countering ethical debate as well as the public or scientific perception 
regarding previously strong positions as to the point where life begins, 
personhood, religious influences, the potentiality of an embryo, the associated 
empirical or cognitive faculties associated with the definition of person, as well as 
the issue of the right to life of an embryo.   
In addition, employing induced pluripotency as an alternative method of obtaining 
embryonic-like-stem cells dispels the necessity of other alternative methods of 
obtaining embryonic-like stem cells for the same reason outlined above; namely, 
that supernumery IVF embryos are not needed to obtain stem cells; that the social 
issue of sourcing human eggs is unnecessary as induced pluripotency can be 
performed on somatic cells; and that there is no need to deliberately maim a 
viable embryo as there is no requirement for any kind of embryo in the first place.  
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In light of these findings it can be concluded that induced pluripotent stem 
cells alleviate or resolve the ethical debate related to the use of human 
embryonic stem cells.  
Induced pluripotency provokes its own ethical problems. Although primarily 
research based, they have ethical ramifications if not adequately addressed. A 
significant concern of induced pluripotency is related to the specific transcription 
factors which are used to stimulate pluripotency within a differentiated cell. 
Noteworthy is the factor c-Myc which has been established as a primary 
contributor to the formation of tumours within stem cell experiments. The ethical 
ramification of this is the possibility of tumour formation in human patients when 
this technology becomes available to clinical trials. It is recommended that further 
research ought to be conducted to establish the possible ramifications of utilising 
different transcription factors. This research should take into account the effect 
on efficiency and differentiation capacity of the resulting stem cells.  
Another important issue related to the induction of pluripotency is the method of 
inserting and activating the necessary transcription factors within a cell. As 
explored above, the different methods which are currently being utilised in this 
area of research involve the use of viral systems, namely retroviral and lentiviral. 
A considerable problem with the use of these systems is the possible genetic 
incorporation of the virus into the resulting stem cell lines, which also may cause 
unknown repercussions further down the line when clinical experiments in human 
trials begin.  
The final ethical issue related to induced pluripotent stem cells is related to the 
social issue of justice. While part of the attraction to this method is its possible 
global application, this universal availability of generic stem cells in stem cell 
banks can be described as a pipe dream. In a climate where third world countries 
are struggling to address basic health problems due to the costs associated with 
doing so, it is highly unlikely that induced pluripotent stem cells, as well as 
possible cures resulting from research conducted on same, will be made 
available to those who inhabit these countries. 
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It is recommended that going forward, researchers who invest in utilising induced 
pluripotent stem cells in their search for treatments and cures of the world's most 
degenerative diseases, bear in mind the need to keep the costs of doing so down, 
or at the very least attempt to do so once the correct method of obtaining same 
has occurred.  
The second half of this thesis was aimed at analysing whether induced pluripotent 
stem cells solved the legal dilemmas caused by human embryonic stem cells. 
Through the analysis it was found that the current legal context which governs 
stem cell research, collection and storage varies significantly from country to 
country. This was established as being due to the diverging cultural, social, and 
historical influences which are unique to each country. Hence, although the 
introduction of induced pluripotent stem cells does alleviate the need to legally 
define the point where life begins, as well as when personhood is ascribed, it 
does not appear to clarify the numerous legal issues related to stem cell 
regulation.  
As one of the most important legal issues of stem cell research, the protection 
and respect of the embryo is not adequately resolved through the employment of 
induced pluripotent stem cells. This is due to the claim that it may be possible, 
perhaps not at the current point in time but in a few years, for scientists to create 
sex cells through the use of inducing pluripotency in somatic skin cells. Ethical 
and social ramifications of this would be that these new sex cells are to be treated 
as such and so are also therefore capable of becoming embryos if united. 
However, this appears to contradict the initial purpose of attempting to find an 
alternative method of creating embryonic-like-cells in the first place; namely, 
circumventing the ethical and legal dilemmas posed by human embryonic stem 
cells.  
The legal issue of consent was essentially indistinguishable between human 
embryonic stem cells and that of induced pluripotent stem cells. This is due to the 
fact that the issue of consent is quite misleading when it comes to stem cells. 
Where consent is usually a once off necessity for a singular medical procedure, 
in the context of cells donated for stem cell research the consent obtained may 
not encompass all medical procedures which the cells may be used in.  
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This is because the consent given will not be limited to the initial establishment 
of a stem cell. In fact, the genetic blueprint of the individual remains within the 
stem cell line for as long as it exists and the applications of same are numerous 
in number. The primary issue with this is that researchers are unable to 
adequately inform cell donors of the possible future uses of their cells. This is due 
to the fact that stem cell research is still very much in its primary stages of 
development; i.e. it is currently unknown how many applications might be 
possible with these stem cells. In order to adequately address this problem, it is 
recommended that until researchers are able to absolutely inform donors how 
their cells will be utilised, a general outline of possible uses for the resulting stem 
cells derived from their donations should be supplied to them. From this general 
outline, they might be able to choose which area of research and application they 
would be happy for their cells to be used in.  
Another major legal issue relating to stem cell research is that of patenting. 
Applicable to both human embryonic stem cells as well as induced pluripotent 
stem cells, patenting is an important aspect of scientific research. Through the 
analyses made within chapters six and seven, it was found that current legislation 
which regulates the patentability of human embryonic stem cells is strictly 
regulated, and in most countries banned as the patenting of these stem cells 
would be contrary to public morality and order. However, as is the case in Europe, 
the European Patenting Office will authorise the patenting of isolate elements of 
the human body, but only if these elements establish more than a discovery, i.e. 
an invention and which are not based on the destruction of a human embryo.  
In this way it appears that the production of induced pluripotent stem cells may 
be authorised, due to the fact that the discovery and production of induced 
pluripotent stem cells are not based upon the destruction of a human embryo, as 
well as the fact that these stem cells can be described as isolated elements of 
the human body. If anything the permissibility of patenting induced pluripotent 
stem cells may encourage researchers to abandon the pursuit of human 
embryonic stem cells and endeavour to further explore induced pluripotent stem 
cells.  
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That said, a major issue which has delayed investment into induced pluripotent 
stem cell research is the fact that over broad patents are being issued to large 
companies, which has caused little leeway for smaller investors to recoup any 
money devoted to more detailed stem cell research.  
Through the appraisal of the legal issues and questions pertaining to both 
embryonic and induced stem cells it does not appear as if the introduction 
of induced pluripotent stem cells as an alternative alleviates the majority of 
the legal issues of human embryonic stem cells. 
Further research into harmonizing stem cell laws and regulations is 
recommended to take place worldwide, as well as clarification and solutions to 
legal questions which may affect stem cell research such as informed consent, 
over-broad patenting, and the legal interpretations of biological boundaries. The 
importance of human embryonic stem cells ought to be highlighted as well. To 
perfect the technique of inducing pluripotency, such stem cells will need to be 
compared to the 'Golden Standard' of embryonic stem cells. Until this standard 
has been reached, and all scientific barriers have been overcome, induced 
pluripotent stem cells will not be employed to their fullest extent.  
While the promise of a life devoid of disease is within our reach, significantly more 
research is needed to make such an ideal a reality.  
 
While induced pluripotent stem cells resolve the majority of ethical issues 
related to human embryonic stem cells, they also generate ethical issues 
of their own. As well as this, induced pluripotent stem cells do little to 
dissipate the majority of the legal issues related to human embryonic stem 
cells. 
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Appendix 1: Timeline 
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Appendix 1: Timeline Continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
2006
•Three different research groups in the US and Japan report being able to reprogram somatic cells to 
embryonic-like cells from mouse skin cells (fibroblasts)
2007
•Shinya Yamanka and his team replicate this procedure using human fibroblasts for the first time. 
•James Thomson and his team also achieved the same feat, using slightly different transcription methods. 
2008
•Lowry et al achieved a successful outcome of embryonic-like stem cells through the same method the 
Japanese team employed.
2009
•Dr. Rudolf Jaenisch found a way to remove the viruses and genes which were part of the cause of tumor 
formation in the iPS cells.
•it was demonstrated that generation of iPS cells is possible without any genetic alteration of the adult 
cell.
2012
•Shinya Yamanka and a fellow developmental biologist, SirJohn Gurdon, are awarded the Nobel Price "for 
the discovery that mature cells can be reprogrammed to become pluripotent." (wiki) :O 
•Researchers from Austria, Hong Kong and China present a protocol for generating human induced 
pluripotent stem cells from exfoliated renal epithelial cells present in urine
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Appendix 2: Comparison of Stem Cell Laws (7) 
Country 
 
 
Position to human 
embryonic stem 
cell Research 
Laws or Court 
Decisions relating to 
human embryonic stem 
cell research 
Advising Bodies 
Ireland -In 2008 there was 
a move to ban 
research on human 
embryos and to 
implement criminal 
charges if research 
took place, but this 
was never passed 
into law  
-Withdrawn: Stem Cell 
Research (Protection of 
Human Embryos) Bill 
2008 
-Lapsed: 
Human Body Organs 
and Human Tissue Bill 
2008  
-M.R. vs. T.R.  
 
-Abolished: Irish 
Council of Bioethics 
-Irish Medical Council 
UK -Allowed, subject to 
a licence from the 
HFEA 
-Embryos can be 
created only for 
research purposes 
-This licence only 
covers research on 
embryos created in 
vitro up to 14 days 
old 
-Human Fertilisation 
and Embryology Act 
1990 & 2008 
-Human Fertilisation 
and Embryology 
Regulations 2001 
-Human Tissue act 
2004 
-Human Reproductive 
Cloning Act 2002 
-Human Tissue 
Authority 
-HFE Authority 
-UK Stem Cell 
Initiative 
Italy -Derivation of 
embryonic stem 
cells is banned, but 
imported embryonic 
stem cell lines may 
be used for 
research  
-Law 40, Regulation of 
Medically Assisted 
Human Reproduction, 
February 2004 
-Referendum on Law 
40, 2005 
-Italian National 
Ethics Committee  
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Appendix 2: Comparison of Stem Cell Laws Continued 
Country Position to 
human 
embryonic stem 
cell Research 
Laws or Court 
Decisions relating to 
human embryonic 
stem cell research 
Advising Bodies 
Spain -Research on 
embryos for 
therapeutic and 
research purposes 
is authorised 
-The creation of 
embryos 
specifically for 
research is 
allowed 
-Law on Biomedical 
Research (Law 
14/2007) 
-Law on Assisted 
Reproductive 
Technology (Law 
22/2006) 
-Law on Assisted 
Reproductive 
Techniques (Law 
45/2003) 
-Guarantees 
Commission for the 
Donation and Use of 
Human Cells and 
Tissues 
-National 
Commission on 
Assisted Human 
Reproduction  
France -Research not 
allowed, except 
under specific 
conditions 
-Creation of 
embryos for 
research is 
banned 
-Law on Bioethics, LOI 
No 2011-814 2011 
-Law on Bioethics, Law 
n. 2004-800 2004 
-Law on Human Life, 
Law n. 94-653 1994 
-French Biomedicine 
Agency 
-French National 
Consultative 
Committee of Ethics 
Germany -Derivation of 
human embryonic 
stem cell is 
banned 
-Embryonic stem 
cell lines created 
before 1st May 
2007 (originally 1st 
January 2002)  
can be imported 
for research 
purposes 
-Embryo Protection Act 
(Embryonenschutzes) 
1991 
-Stem Cell Act 
(Stammzellgesetz) 
2002 
-Act for the Protection 
of embryos 1990 
-German Constitution, 
basic law, 1949 
-Central Ethics 
Commission for Stem 
Cell Research (ZES) 
-Germany National 
Ethics Council  
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Appendix 2: Comparison of Stem Cell Laws Continued 
Country Position to human 
embryonic stem 
cell Research 
Laws or Court 
Decisions relating to 
human embryonic stem 
cell research 
Advising Bodies 
United 
States 
-The creation of 
embryos 
specifically for 
research purposes 
is prohibited 
-Only research on 
already existing 
stem cell lines 
created prior to 9th 
August 2001 is 
permitted 
-Dickey-Wicker 
Amendment 1995 
-Stem Cell Therapeutic 
and Research Act 2005 
-Roe v. Wade 1973 
-Individual State laws 
range from outright 
banning human 
embryonic stem cell 
research to funding its 
development 
-NIH Human Embryo 
Research Panel 
-United States 
National Academies 
-Human Embryonic 
Stem Cell Research 
Advisory Committee 
-Centre for Biologics 
Evaluation and 
Research (CBER) 
 
Japan -Research is 
allowed for 
therapeutic 
purposes  
 
 
- Pharmaceutical Affairs 
Law 
 
 
-Ministry of Health, 
Labour and Welfare 
(MHLW) 
-Pharmaceuticals 
and Medical Device 
Agency (PMDA) 
European 
Union & 
The 
Council of 
Europe 
Due to the diversity 
of philosophical, 
social, cultural and 
religious influences 
of each member 
state, the EU has 
not issued a direct 
law in relation to 
human embryonic 
stem cell research. 
-EU Tissues and Cell 
Directive 2004/23/EC 
-European Convention 
on Human Rights and 
Biomedicine (1997) 
-Group of Advisors 
on the Ethical 
Implications of 
Biotechnology (now 
known as the EGE) 
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Appendix 3: World Map of Stem Cell Policies (57) 
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